

FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER:
0512-1004

U.S. PCT No. 10/049381

INTERNATIONAL APPLICATION NO.:
PCT/FR00/023212

INTERNATIONAL FILING DATE:
11 AUGUST 2000 (11.08.00)

PRIORITY DATE CLAIMED:
13 AUGUST 1999 (13.08.99)

TITLE OF INVENTION: PHENANTHROLINE-7-ONE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS

APPLICANT(S) FOR DO/EO/US: Evelynne DEFOURNE, Francis DARRO, Jean BASTIDE, Robert KISS and Armand FRYDMAN

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
 2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
 3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
 4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau **--in French language**).
 - b. ☐ has been transmitted by the International Bureau. (see attached copy of PCT/IB/308)
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
 6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
 8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
 9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
 10. ☐ A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Item 11. to 16. below concern document(s) or information included:
11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
 12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 13. ☒ A **FIRST** preliminary amendment.
 14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
 15. ☐ A substitute specification.
 16. ☒ A change of power of attorney and/or address letter.
 16. ☒ Other items or information: INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT/IPEA/409), INTERNATIONAL SEARCH REPORT (PCT/ISA/210), APPLICATION DATA SHEET, ABSTRACT

12 FEB 2002

U.S. APPLICATION NO. *(unknown, see 37 CFR 1.5)* **10/049381**

INTERNATIONAL APPLICATION NO.
PCT/FR00/02312

ATTORNEY'S DOCKET NO.
0512-1004

17. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Neither international preliminary examination fee (37 CFR1.482) nor international search fee (37 CFR1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	\$ 1,040.00
---	-------------

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	\$ 890.00
---	-----------

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$ 740.00
--	-----------

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$ 710.00
---	-----------

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	\$ 100.00
---	-----------

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than _____ months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	14 - 20 =	0	X \$18.00
Independent claims	6 - 3 =	3	X \$84.00
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			+ \$280.00

TOTAL OF ABOVE CALCULATIONS =

\$ 1142.00

Reduction of ½ for filing by small entity, if applicable. Applicant claims Small Entity Status under 37 CFR 1.27.

\$

SUBTOTAL =

\$ 1142.00

Processing fee of \$130 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR1.492(f)).

\$

TOTAL NATIONAL FEE =

\$ 1142.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

\$

TOTAL FEES ENCLOSED =

\$ 1182.00

Amount to be refunded:

charged:

- | | | |
|----|---|--|
| a. | X | A check in the amount of \$ 1182.00 to cover the above fees is enclosed. |
| b. | | Please charge my Deposit Account No. 25-0120 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed. |
| c. | X | The Commissioner is hereby authorized to charge any additional fees which may be required by 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. 25-0120 . A duplicate copy of this sheet is enclosed. |

SEND ALL CORRESPONDENCE TO:

YOUNG & THOMPSON
745 South 23rd Street
2nd Floor
Arlington, VA 22202
(703) 521-2297
facsimile (703) 685-0573

February 12, 2002

By

Benoît Castel
Attorney for Applicant
Registration No. 35.041

Customer Number: 000466

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Evelyne DELFOURNE et al.

Serial No. (unknown)

Filed herewith

PHENANTHROLINE-7-ONE DERIVATIVES
AND THEIR THERAPEUTIC APPLICATIONS

PRELIMINARY AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to the first Official Action and calculation of the filing fee, please substitute specification page 11 as originally filed, with new page 11 as filed in the Article 34 amendment of July 27, 2001. New specification page 11 is marked "AMENDED SHEET" and is attached hereto.

Please substitute Claims 1-12 as originally filed, which appear on pages 57-71, with Claims 1-14 as filed in the Article 34 amendment of July 27, 2001. The pages containing Claims 1-14 are marked "AMENDED SHEET" and are attached hereto. Following the insertion of Claims 1-14, please amend these claims as follows:

IN THE CLAIMS:

--6.(Amended) The use of a compound as defined in claim 1, for the manufacture of an anticancer drug.--

Evelyne DELFOURNE et al.

IN THE ABSTRACT:

Please replace the abstract as originally filed which appears on the cover sheet of the Published application. Add new abstract as enclosed herewith on a separate sheet.

R E M A R K S

The above changes in the specification and claims merely place this national phase application in the same condition as it was during Chapter II of the international phase, with the multiple dependencies being removed. Following entry of this amendment by substitution of the pages, only claims 1-14 remain pending in this application. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

Respectfully submitted,

YOUNG & THOMPSON

By



Benoît Castel
Attorney for Applicant
Customer No. 000466
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
703/521-2297

February 12, 2002

DATE _____ TIME _____

10

6. (Amended)



ABSTRACT

The invention concerns a pharmaceutical composition comprising an efficient amount of a compound selected among the compounds of formulae (I) and (Ia) wherein: R1, R2, R3, R4, R5, R6 and R7 are as defined in Claim 1. Said (Ia) compounds have interesting cytotoxic properties leading to a therapeutic use as antitumoral medicines.

ABSTRACT


The invention concerns a pharmaceutical composition comprising an efficient amount of a compound selected among the compounds of formulae (I) and (Ia). The compounds have interesting cytotoxic properties leading to a therapeutic use as antitumoral medicines.

Formula IIa



Formula IIIa

Formula IVa



Formula Ia

AMENDED SHEET

WO 01/12631

1

PCT/FR00/02312

Phenanthroline-7-one derivatives and their therapeutic applications

The present invention relates to pharmaceutical compositions based on polyaromatic compounds of use in particular as antitumour medicaments.

In 1999, cytotoxic treatments (chemotherapy) used to reduce the size of cancerous tumours, to suppress the development of the tumour process or indeed even, in still too few cases, to eliminate clumps of cancer cells and the risk of metastases, combine chemical substances which have been recently introduced with others which have been used for several decades. For example, 5-fluorouracil (5-FU), recognized for nearly 40 years as one of the most active treatments for colorectal cancer, can be replaced by one or other of the specific inhibitors of topoisomerase I (irinotecan or topotecan) when the tumour is no longer sensitive to 5-FU. More generally, the therapeutic arsenal available for treating colorectal tumours will also be enriched with the availability of oxaliplatin, novel in situ "donors" of 5-FU or selective inhibitors of thymidylate synthetase. This coexistence is not limited to the treatment of colorectal cancers since, in addition, the chemotherapy of breast, ovarian and lung cancers now makes wide use of the family of taxane derivatives (paclitaxel, docetaxel). The need for more effective and better tolerated treatments, thus improving the survival and the quality of life of the patients, is imperative since, still taking the example of colorectal tumours, it has been estimated (S.L. Parker, T. Tong, S. Bolden et al., CA Cancer J. Clin., 1997) that, in the United States alone, over 131 000 new cases were diagnosed in 1997, 54 000 of which were responsible for the death of the patient. It is the awareness of this situation which has prompted the inventors to focus their attention on a family of

- 2 -

studied, identified in Ascidians of warm seawaters, to develop a novel medicinal chemistry intended to select synthetic compounds derived from a design/chemical modulation study and having significant therapeutic
5 cytotoxic activity.

The seas and oceans which cover more than 70% of the surface of the globe harbor marine plants and sponges whose gradual systematic pharmacognosic study shows
10 that these living species can contain complex alkaloids that have advantageous pharmacological properties. For example, the sponges *Cryptotheca crypta* and *Halichondria okadai* have been the subject of extensive studies since the discovery of the presence, in their
15 cells, of cytarabine or of halichondrine B. This is likewise the case for the family of tunicates, since the isolation of aplidin from the tunicate *Aplidium albicans* which lives in the Balearic islands (Spain). Alkaloids of tetrahydroisoquinolone structure have been
20 isolated from the ascidian *Ecteinascidia turbinata*. Among these, ecteinascidin-743 has been the subject of extensive preclinical studies (E. Igbicka et al., NCI-EORTC symposium, 1998; Abst. 130 p. 34), and also clinical trials intended to define its therapeutic
25 potential as an anticancer drug (A. Bowman et al., NCI-EORTC symposium, 1998; Abst. 452 p. 118; M. Villanova-Calero et al., NCI-EORTC symposium, 1998; Abst. 453 p. 118; M.J.X. Hillebrand et al., NCI-EORTC symposium, 1998; Abst. 455 p. 119; E. Citkovic et al.,
30 NCI-EORTC symposium, 1998; Abst. 456 p. 119). Novel pentacyclic acridine derivatives have also been the subject of pharmacochemical studies (D.J. Hagan et al., J. Chem. Soc., Perkin Transf., 1997; 1: 2739-2746).

35 Another natural alkaloid of marine origin, ascididemin, has been extracted from the tunicate *Didemnum* sp. (J. Kobayashi et al., Tetrahedron, lett. 1988; 29: 1177-80) and from the ascidian *Cystodytes dellechiaiei* (I. Bonnard et al., Anti-cancer Drug design 1995; 10:


333-46). Ascididemin possesses antiproliferative properties demonstrated on the model of mouse leukemia (lines P388 or L1210) and described by F. Schmitz et al. (J. Org. Chem. 1991; 56: 804-8), B. Lindsay et al. (Bioorg. Med. Chem. Lett. 1995; 5: 739-42) and J. Kobayashi et al. (Tetrahedron Lett. 1988; 29: 1177-80) and on the model of human leukemia described by I. Bonnard et al. (Anti-cancer Drug design 1995; 10: 333-46). Several routes for synthesizing ascididemin have been reported by various authors: F. Bracher et al. (Heterocycles 1989; 29: 2093-95), C.J. Moody et al. (Tetrahedron Lett. 1992; 48: 3589-602) and G. Gellerman et al. (Synthesis 1994; 239-41).

Mention may also be made of 2-bromoleptoclinidone (according to the naming by S.J. Bloor et al. 1987) isolated from the ascidian *Leptoclinides* sp. by S.J. Bloor et al. (J. Ann. Chem. Soc. 1987; 109: 6134-6) and synthesized by F. Bracher et al. (Hétérocycles 1989; 29: 2093-95) and then by M.E. Jung et al. (Hétérocycles 1994; 39; 2: 767-778). 2-Bromoleptoclinidone shows cytotoxicity on the cellular model of leukemia with an ED₅₀ of 0.4 µg/ml. The cytotoxic properties were confirmed by F. Bracher (Pharmazie 1997; 52: 57-60) both *in vitro* - on sixty tumor cell lines in culture - and *in vivo* on models of xenographs of human tumor cell lines (colon tumors SW-620 and HTC116, renal tumor A498 and melanoma LOX IM VI) implanted into mice.


Other compounds derived from ascididemin, such as 11-hydroxy ascididemin, 11-methoxy ascididemin, 11-phenyl and 11-nitrophenyl ascididemin, 1-nitro and 3-nitro ascididemin and neocalliactin have been chemically described (according to the numbering by S.J. Bloor et al. 1987) by various teams such as those of F.J. Schmitz (J. Org. Chem. 1991; 56: 804-8) and Y. Kitahara et al. (Heterocycles 1993; 36: 943-46; Tetrahedron Lett. 1997; 53, 17029-38), G. Gellerman et

al. (Tetrahedron lett. 1993; 34: 1827-30), S. Nakahara et al (Heterocycles 1993; 36: 1139-44), I. Spector et al. (US Patent Number: 5,432,172, Jul. 11, 1995).

- 5 One subject of the present invention is a pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of general formulae I and Ia below:



Formula I




Formula Ia

10

in which:

- X is chosen from oxygen, an =NH group and an =N-OH group,
- 15 - R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₂ is chosen from hydrogen and halogens,
- 20 - R₃ is chosen from hydrogen, halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl groups and groups
- 25 -(CH₂)_n-Y with Y being chosen from halogens and CN, -CH(O-Et)₂, (C₁-C₆) alkoxy, -O-(CH₂)₂-N(CH₃)₂ and -N(CH₃)₂ groups and n = 1 to 3,
- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are
- 30 chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₅, R₆ and R₇ are chosen from:
hydrogen or a halogen atom,
C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, (C₁-C₆)-
alkoxy(C₁-C₆)alkyl, (C₁-C₄)alkylcarbonyloxy(C₁-C₄)alkyl,
5 -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups,
-NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen,
independently of each other, from hydrogen and (C₁-C₆)
alkyl, -phenyl-CO-CH₃ and -CH₂-CH₂-N(CH₃)₂ groups,
-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂,
10 morpholino, nitro or SO₃H groups,
groups:



- 15 R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar
being a C₆-C₁₄ aryl group,
with the exclusion of the compounds of formula I
containing the combination:


- X = O,
20 and, either: R₁, R₂, R₃, R₄, R₅, R₆, R₇ = H,
or : R₁, R₃, R₄, R₅, R₆, R₇ = H and R₂ = Br,
and with the exclusion of the compound formula Ia
containing the combination X = O and R₁, R₂, R₃, R₄, R₅,
R₆, R₇ = H,
25 and the addition salts of these compounds with
pharmaceutically acceptable acids.

- The present invention relates more particularly to a
pharmaceutical composition comprising an effective
30 amount of a compound chosen from the compounds of
formula I in which:

- X is chosen from oxygen, an =NH group and an
=N-OH group,
- R₁ is chosen from hydrogen, halogens, a nitro
35 group and groups -NR₈R₉ in which R₈ and R₉ are chosen,
independently of each other, from hydrogen and (C₁-C₄)
alkyl groups,

independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from hydrogen, halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl, -(CH₂)₂-N(CH₃)₂, and -(CH₂)₂-O-(CH₂)₂-N(CH₃)₂ groups,
- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₅, R₆ and R₇ are chosen from:
hydrogen or a halogen atom,
C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ groups in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl and -CH₂-CH₂-N(CH₃)₂ groups,
-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂, morpholino, nitro or SO₃H groups,
groups:



25

R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,
with the exclusion of the compounds in which X = O,
and, either : R₁, R₂, R₃, R₄, R₅, R₆, R₇ = H, or : R₁, R₃, R₄, R₅, R₆, R₇ = H and R₂ = Br,

and the addition salts of these compounds with pharmaceutically acceptable acids.

35 One subject of the present invention is more particularly a pharmaceutical composition comprising an

- X represents oxygen,
- R₁ is chosen from hydrogen and an amino group,

- R₄ is chosen from hydrogen, halogens and nitro and amino groups,

and the addition salts of these compounds with pharmaceutically acceptable acids.

- X represents oxygen,
- R₁ is chosen from hydrogen and an amino group,

- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from hydrogen, halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, methyl groups, (C₁-C₄) phenylalkyl groups and groups -(CH₂)_n-Y with Y being chosen from halogens and groups CN, -CH(O-Et)₂, (C₁-C₆) alkoxy, -O-(CH₂)₂-N(CH₃)₂ and -N(CH₃)₂ and n = 1 to 3,

- 8 -

- R_4 is chosen from hydrogen, halogens, and nitro and amino groups,

- R_5 is chosen from a hydrogen, a halogen and a methoxy group,

5 - R_6 and R_7 are chosen from hydrogen and C_1-C_6 alkoxy, (C_1-C_6) alkoxy (C_1-C_6) alkyl and $-CH_2OCOCH_3$ groups,

with the exclusion of the compounds of formula I in which $R_1, R_2, R_3, R_4, R_5, R_6, R_7 = H$ or $R_1, R_3, R_4, R_5, R_6, R_7 = H$ and $R_2 = Br$, and of the compound of formula

10 Ia in which $R_1, R_2, R_3, R_4, R_5, R_6, R_7 = H$,

and the addition salts of these compounds with pharmaceutically acceptable acids.

A subject of the present invention is also the compounds of formula I as defined above, with the exclusion of the compounds in which $X = O$, and

either $R_1, R_2, R_3, R_4, R_5, R_6, R_7 = H$,

or $R_1, R_3, R_4, R_5, R_6, R_7 = H$ and $R_2 = Br$,

or $R_1, R_2, R_4, R_5, R_6, R_7 = H$ and $R_3 = OCH_3$,

20 or $R_1, R_2, R_3, R_4, R_6, R_7 = H$ and $R_5 = OH$ or OCH_3 ,

or $R_1 = NO_2$ and $R_2, R_3, R_4, R_6, R_7 = H$,

and the addition salts of these compounds with pharmaceutically acceptable acids.

25 A subject of the present invention is also the compounds of formula Ia as defined above, with the exclusion of the compound in which $X = O$ and $R_1, R_2, R_3, R_4, R_5, R_6, R_7 = H$,


30 and the addition salts of these compounds with pharmaceutically acceptable acids.

The expression "addition salts with pharmaceutically acceptable acids" denotes salts which give the biological properties of the free bases, without having
35 any adverse effects. These salts may be especially those formed with mineral acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid; acidic metal salts, such as disodium

orthophosphate and monopotassium sulfate, and organic acids.

In general, the compounds of formula I are obtained according to the general reaction scheme described by F. Bracher et al. (Heterocycles 1989; 29: 2093-95) for ascididemin. According to this scheme, the compounds are prepared by oxidative amination of a 5,8-quinone substituted with a substituted ortho-aminoacetophenone, followed by cyclization of the diarylamine obtained (compounds of the formula II) into an intermediate tetracyclic quinone (compounds of formula III). The enamine formed by reaction of the compound of formula III with dimethylformamide diethyl acetal gives the final derivative by cyclization:

Scheme I



5

10


15

20

25

30

Scheme II



Certain compounds may be prepared directly from the ascididemin isomer known as 9-*H*-quino[4,3,2-*de*]-[1,7]phenanthrolin-9-one, or from a compound of formula Ia used as a synthetic intermediate.

5

Certain compounds may be prepared directly from the ascididemin isomer known as 9-*H*-quino[4,3,2-*de*]-[1,7]phenanthrolin-9-one, or from a compound of formula Ia used as a synthetic intermediate.

10

Thus, in particular, the compounds of formula Ia in which R₃ is a group -NR₁₀R₁₁, in which R₁₀ and/or R₁₁ are other than hydrogen, may be obtained from a compound of formula Ia in which R₃ is a -NH₂ group.

15

A - Preparation of the intermediate products of formula II (Scheme I)

20 A-1 - Synthesis of 6-(2-acetyl-4-methylphenylamino)-quinoline-5,8-dione (Intermediate A₁) (CRL 8322)

A solution of 5,8-quinolinedione (0.215 g, 1.35 mmol) in 12 ml of ethanol is added slowly to a solution of cerium chloride (1 g, 2.7 mmol) and 5-methyl-2-aminoacetophenone (0.402 g, 2.7 mmol) in 5 ml of ethanol. The reaction medium (red) is stirred overnight at room temperature. The resulting medium is hydrolyzed with 30 ml of aqueous 10% acetic acid solution and extracted 4 times with chloroform. The organic phases are dried over MgSO₄ and then evaporated. The crude product obtained is purified by flash chromatography on a column of silica (95/5 CH₂Cl₂/MeOH) to give 0.405 g of the expected tricyclic compound in the form of a powder:

35

- Yield = 98%
- ¹H NMR (CDCl₃): 2.42 (s, 3H), 2.77 (s, 3H), 6.86 (s, 1H), 7.38 (dd, 1H, J = 8 and 1.6 Hz), 7.52 (d, 1H, J = 8 Hz), 7.61 (dd, 1H, J = 5.2 and 7.6 Hz), 7.74 (d,

1H, J = 1.6 Hz), 8.46 (dd, 1H, J = 7.6 and 5.2 Hz),
9.02 (dd, 1H, J = 2 and 5.2 Hz), 11.18 (s, 1H).

**A-2 - Synthesis of 6-(2-acetyl-4-chlorophenylamino)quinoline-5,8-dione
(Intermediate A₂)**

Preparation according to the process described in
chapter A-1: quinoline-5,8-dione (0.188 g, 1.18 mmol),
cerium chloride (0.88 g, 2.36 mmol), 5-chloro-2-
aminoacetophenone (0.4 g, 3.14 mmol), ethanol
(10 + 4 ml), acetic acid (25 ml). 0.3 g of a red powder
is obtained:

• Yield = 78%

• ¹H NMR (CDCl₃): 2.65 (s, 3H), 6.84 (s, 1H), 7.52
(dd, 1H, J = 8.8 Hz), 7.57 (d, 1H, J = 8.8 Hz), 7.63
(dd, 1H, J = 8 and 4.4 Hz), 7.89 (d, 1H, J = 2.4 Hz),
8.46 (dd, 1H, J = 0.8 and 8 Hz), 9.02 (dd, 1H, J = 2
and 5.2 Hz), 11.18 (s, 1H).

• ¹³C NMR (CDCl₃): 28.5; 107.36; 121.86; 126.69;
126.85; 127.49; 128.39; 132.10; 134.06; 134.75; 138.36;
143.29; 148.32; 155.22; 181.28; 182.63; 200.39.

**A-3 - Synthesis of 6-(2-acetyl-4-benzylaminophenylamino)quinoline-5,8-dione
(Intermediate A₃)**

Preparation according to the process described in
chapter A-1: quinoline-5,8-dione (0.250 g, 1.57 mmol),
cerium chloride (0.77 g, 3.14 mmol), 5-benzylamino-2-
aminoacetophenone (0.603 g, 3.14 mmol), ethanol
(15 + 7 ml), acetic acid (35 ml). 0.56 g of a red
powder is obtained:

• Yield = 91%

• ¹H NMR (CDCl₃): 2.54 (s, 3H), 4.38 (s, 2H), 6.70
(s, 1H), 6.83 (dd, 1H, J = 9.6 and 3.2 Hz), 7.08 (d,
1H, J = 3.2 Hz), 7.30-7.37 (m, 5H), 7.43 (d, 1H, J =
9.6 Hz), 7.58 (dd, 1H, J = 7.6 and 4.8 Hz), 8.43 (dd,
1H, J = 7.6 and 2 Hz), 9.03 (dd, 1H, J = 2 and 4.8 Hz),
10.67 (s, 1H).

A-4 - Synthesis of 6-(2-acetyl-5-bromophenylamino)quinoline-5,8-dione (Intermediate A₄) (CRL 8268)

Preparation according to the process described by
5 F. Bracher, Liebigs Ann. Chem. 1990, 205-206.

A-5 - Synthesis of 6-(2-acetyl-4-dimethylaminophenylamino)quinoline-5,8-dione (Intermediate A₅)

10 Preparation according to the process described in chapter A-1: quinoline-5,8-dione (0.36 g, 2.26 mmol), cerium chloride (1.67 g, 4.49 mmol), 5-dimethylamino-2-aminoacetophenone (0.8 g, 4.49 mmol), ethanol (20 + 10 ml), acetic acid (50 ml). 1.26 g of a red
15 powder are obtained:

- Yield = 84%
- ¹H NMR (CDCl₃): 2.85 (s, 3H), 3.12 (s, 6H), 6.72 (s, 1H), 6.90 (dd, 1H, J = 2.8 and 9.2 Hz), 7.15 (d, 1H, J = 2.8 Hz), 7.49 (d, 1H, J = 9.2 Hz), 7.58 (dd, 20 1H, J = 8 Hz and 4.4 Hz), 8.43 (dd, 1H, J = 1.6 and 8 Hz), 9.00 (dd, 1H, J = 1.6 and 4.4 Hz), 10.69 (s, 1H).

A-6 - Synthesis of 6-(2-acetyl-4-methoxyphenylamino)quinoline-5,8-dione (Intermediate A₆)

25 Preparation according to the process described in chapter A-1: quinoline-5,8-dione (3.51 g, 22.08 mmol), cerium chloride (16.4 g, 44.03 mmol), 5-methoxy-2-aminoacetophenone (7.29 g, 44.18 mmol), ethanol (200 + 90 ml), acetic acid (500 ml). 4.25 g of a red
30 powder are obtained:

- Yield = 60%
- ¹H NMR (CDCl₃): 2.65 (s, 3H), 3.87 (s, 3H), 6.76 (s, 1H), 7.12 (dd, 1H, J = 2.8 and 8.8 Hz), 7.42 (d, 1H, J = 2.8 Hz), 7.55 (d, 1H, J = 8.8 Hz), 7.61 (dd, 1H, J = 7.6 and 4.4 Hz), 8.45 (dd, 1H, J = 1.6 and 7.6 Hz), 9.01 (dd, 1H, J = 1.6 and 4.4 Hz), 10.80 (s, 1H).

A-7 - Synthesis of 4,6-bis(2-acetylanilino)quinoline-5,8-dione (Intermediate A₇)

Preparation according to the process described in chapter A-1: 4-chloroquinoline-5,8-dione (3.5 g, 18 mmol), cerium chloride (13.5 g, 36.24 mmol), 2-aminoacetophenone (4.4 ml, 36 mmol), ethanol (160 + 70 ml), acetic acid (400 ml). 2.32 g of a red powder are obtained:

- Yield = 30%
- ¹H NMR (CDCl₃): 2.69 (s, 3H), 2.72 (s, 3H), 6.85 (s, 1H), 7.18 (ddd, 1H, J = 7.6 and 7.6 and 0.8 Hz), 7.28 (m, 1H), 7.30 (d, 1H, J = 6.4 Hz), 7.54-7.59 (m, 3H), 7.63 (d, 1H, J = 7.6 Hz), 7.91 (dd, 1H, J = 1.6 and 8.4 Hz), 7.94 (dd, 1H, J = 1.2 and 8.4 Hz), 8.47 (d, 1H, J = 6.4 Hz), 11.35 (s, 1H), 12.35 (s, 1H).

A-8 - Synthesis of 6-(2-acetyl-4-bromophenylamino)-4-methoxyquinoline-5,8-dione (Intermediate A₈)

Preparation according to the process described in chapter A-1: 4-methoxyquinoline-5,8-dione (1.57 g, 9.1 mmol), cerium chloride (3.1 g, 8.3 mmol), 5-bromo-2-aminoacetophenone (Leonard, Boyd, J. Org. Chem. 1946; 11, 419-423) (1.95 g, 9.1 mmol), ethanol (200 ml), acetic acid (180 ml). After purification by flash chromatography on a column of silica (95/5 CH₂Cl₂/MeOH), 1.22 g of an orange powder are obtained:

- Yield = 37%
- ¹H NMR (CDCl₃): 3.15 (s, 3H), 4.58 (s, 3H), 7.61 (d, 1H, J = 6 Hz), 7.74 (s, 1H), 7.99 (d, 1H, J = 8.8 Hz), 8.14 (dd, 1H, J = 8.8 and 2.4 Hz), 8.51 (d, 1H, J = 2.8 Hz), 9.32 (d, 1H, J = 6 Hz), 11.68 (s, 1H).

A-9 - Synthesis of 2-methoxy-6-(2-acetylphenylamino)quinoline-5,8-dione (Intermediate A₉)

A solution of o-aminoacetophenone (0.41 g, 3.1 mmol) in ethanol (6 ml) is added to a suspension of 2-methoxyquinoline-5,8-dione (0.54 g, 2.8 mmol) and cerium

- 16 -

chloride (1.16 g, 4.7 mmol) in ethanol (100 ml). The reaction medium is stirred at room temperature for 40 hours. After concentration on a rotary evaporator, the crude product obtained is purified by filtration on silica (98/2 CHCl₃/heptane) to give the expected codensation product in the form of a red powder (0.35 g).

- Yield = 38%
- Melting point = 258°C
- 10 • ¹H NMR (CDCl₃): 2.67 (s, 3H), 4.15 (s, 3H), 6.79 (s, 1H), 6.98 (d, 1H, J = 8.8 Hz), 7.18 (ddd, 1H, J = 8.1, 8.4 and 1.5 Hz), 7.56 (dd, 1H, J = 8.4 and 1.5 Hz), 7.61 (ddd, 1H, J = 8.1 and 8.4 and 1.1 Hz), 7.94 (dd, 1H, J = 8.1 and 1.5 Hz), 8.31 (d, 1H, J = 8.8 Hz).
- 15 • ¹³C NMR (CDCl₃): 28.51, 54.73, 106.02, 115.22, 120.78, 122.50, 123.11, 125.70, 132.34, 134.24, 137.18, 140.05, 143.30, 148.21, 167.75, 180.88, 183.05, 201.41.
- IR (CHCl₃): 1668, 1644 cm⁻¹

A-10 - Synthesis of 3-hydroxymethyl-6-(2-acetylphenylamino)quinoline-5,8-dione (Intermediate A₁₀)

25 a) - 3-Hydroxymethyl-5,8-dimethoxyquinoline

A solution of 1M LiAlH₄/Et₂O (5 ml, 5 mmol) is added dropwise and under nitrogen to a solution of ethyl 5,8-dimethoxyquinoline-3-carboxylate (180 mg, 0.689 mmol) in 60 ml of THF. The mixture is stirred at room temperature for 15 hours and then poured into 15 ml of 1N NaOH and 40 ml of water. After extraction with CH₂Cl₂ (3 × 100 ml) and then drying of the organic phase over MgSO₄, the extract is concentrated on a rotary evaporator. The crude product obtained is purified by flash chromatography (95/5 CH₂Cl₂/MeOH) to give the expected product in the form of a brown powder (72 mg):

- Yield = 48%
- Melting point = 150°C

• ^1H NMR (CDCl_3): 3.92 (s, 3H), 4.00 (s, 3H), 4.88 (s, 2H), 6.72 (d, 1H, $J = 8.4$ Hz), 6.88 (d, 1H, $J = 8.4$ Hz), 8.47 (d, 1H, $J = 2.2$ Hz), 8.87 (d, 1H, $J = 2.2$ Hz)

5 • ^{13}C NMR (CDCl_3): 55.76, 56.00, 63.09, 103.95, 106.70, 121.25, 128.62, 133.35, 139.80, 148.61, 149.21, 149.41.

- IR (CDCl₃): 3607, 3417, 1622, 1605 cm⁻¹.

10 b) - 3-Hydroxymethylquinoline-5,8-dione

A solution of 3-hydroxymethyl-5,8-dimethoxyquinoline (55 mg, 0.25 mmol) and cerium ammonium nitrate (550 mg, 1 mmol) in a CH₃CN/H₂O mixture (3 ml/1 ml) is stirred at room temperature for 40 minutes. After addition of 5 ml of H₂O and 10 ml of saturated NaHCO₃ solution, the medium is extracted with CH₂Cl₂ (6 × 30 ml) and the organic phases are dried over MgSO₃. After evaporating off the solvent on a rotary evaporator, the expected quinone is obtained in the form of a brown powder (11 mg):

- Yield = 22%

- Melting point = 150°C

• ^1H NMR (CDCl_3): 4.95 (s, 2H), 7.06 (d, 1H, J = 10.2 Hz), 7.15 (d, 1H, J = 10.2 Hz), 8.43 (s, 1H), 9.03 (s, 1H).

- ^{13}C NMR (CDCl_3): 62.03, 128.86, 132.26, 138.00, 139.11, 141.33, 146.58, 153.10, 183.12, 184.54.

- IR (CHCl₃): 3413, 1680, 1596 cm⁻¹.

30 c) - Synthesis of 3-hydroxymethyl-6-(2-acetylphenyl-
amino)quinoline-5,8-dione (Intermediate A₁₀)

A solution of 2-aminoacetophenone (0.18 g, 1.33 mmol) is added to a suspension of 3-hydroxymethylquinoline-5,8-dione (0.22 g, 1.16 mmol) and cerium chloride (0.6 g, 2.43 mmol) in ethanol (40 ml). The reaction medium is stirred at room temperature in darkness for 3 hours. After concentrating on a rotary evaporator, the crude product obtained is purified by filtration on silica (98/2 CH₂Cl₂/MeOH) to give the expected

condensation product in the form of a violet powder (0.16 g):

- Yield = 42%
- Melting point = 258°C
- 5 • ^1H NMR (DMSO- d_6): 2.67 (s, 3H), 4.73 (d, 2H, J = 5.5 Hz), 5.67 (t, 1H, J = 5.5 Hz), 6.64 (s, 1H), 7.30 (m, 1H), 7.71 (m, 2H), 8.12 (d, 1H, J = 8.0 Hz), 8.35 (d, 1H, J = 2.0 Hz), 8.93 (d, 1H, J = 2.0 Hz), 11.02 (s, 1H).
- 10 • ^{13}C NMR (CDCl_3): 28.81, 60.08, 106.52, 120.96, 123.44, 126.14, 127.23, 131.52, 132.69, 134.43, 138.91, 141.75, 143.55, 146.62, 152.81, 181.62, 181.84, 202.02.
- IR (CHCl_3): 3440, 1690, 1661, 1640 cm^{-1} .

15

B - Preparation of the intermediate products of formula III (Scheme II)

B-1 - Synthesis of 9,11-dimethyl-1,6-diazanaphthacene-5,12-dione (Intermediate B_1) (CRL 8324)

1.9 ml of sulfuric acid dissolved in 9.6 ml of acetic acid are added slowly to a solution of tricyclic intermediate A_1 (0.4 g, 1.3 mmol) in 12 ml of acetic acid. The reaction medium is refluxed for 30 minutes and, after cooling, is then poured into a beaker containing crushed ice. The mixture is neutralized with NH_4OH and then extracted 4 times with dichloromethane. The organic phases are dried over MgSO_4 and then evaporated. The crude product obtained is purified by flash chromatography on a column of silica (95/5 $\text{CH}_2\text{Cl}_2/\text{MeOH}$) to give 0.325 g of the expected tetracyclic compound.

- Yield = 86%
- 35 • ^1H NMR (CDCl_3): 2.64 (s, 3H), 3.29 (s, 3H), 7.74 (dd, 1H, J = 7.6 and 4.8 Hz), 7.75 (dd, 1H, J = 8.4 and 1.6 Hz), 8.12 (dd, J = 1.6 Hz), 8.33 (d, 1H, J = 8.4), 8.71 (dd, 1H, J = 2 and 7.6 Hz), 9.13 (dd, 1H, J = 2 and 4.8 Hz).

Preparation according to the process described in chapter B-1: tricyclic intermediate A₂ (0.289 g, 0.88 mmol), sulfuric acid (1.3 ml), acetic acid (8 + 6.5 ml). After purification by flash chromatography (95/5 CH₂Cl₂/MeOH), 0.26 g of tetracycle is obtained:

- 15 B-3 - Synthesis of 9-benzylamino-11-methyl-1,6-diazanaphthacene-5,12-dione (Intermediate B₃)

- Yield = 98%
- ¹H NMR (CDCl₃): 3.09 (s, 3H), 4.52 (d, 2H), 4.86 (t, 1H), 7.06 (d, 1H, J = 2.8 Hz), 7.29 (dd, 1H, J = 9.2 and 2.8 Hz), 7.3-7.43 (m, 5H), 7.71 (dd, 1H, J = 4.8 and 8 Hz), 8.20 (d, 1H, J = 9.8 Hz), 8.69 (dd, 1H, J = 1.6 and 8 Hz), 9.09 (dd, 1H, J = 1.6 and 4.8 Hz).

30 Preparation according to the process described by
F. Bracher, Liebigs Ann. Chem. 1990, 205-206.

35 Preparation according to the process described in chapter B-1: intermediate tricycle A₅ (0.76 g, 2.27 mmol), sulfuric acid (3.5 ml), acetic acid (20 + 18 ml). After work-up, 0.67 g of tetracycle is obtained.

- Yield = 93%
- ¹H NMR (CDCl₃): 3.17 (s, 3H), 3.21 (s, 6H), 7.04 (d, 1H, J = 3.2 Hz), 7.51 (dd, 1H, J = 3.2 and 9.2 Hz), 7.71 (dd, 1H, J = 8 and 4.4 Hz), 8.26 (d, 1H, J = 9.2 Hz), 8.7 (dd, 1H, J = 1.6 and 8 Hz) 9.09 (dd, 1H, J = 1.6 and 4.4 Hz).

B-6 - Synthesis of 9-methoxy-11-methyl-1,6-diazanaphthacene-5,12-dione (Intermediate B₆)

10 Preparation according to the process described in
chapter B-1: intermediate tricycle A₆ (4.25 g,
13.18 mmol), sulfuric acid (20 ml), acetic acid
(110 + 100 ml). The product obtained by flash
chromatography (100/3 CH₂Cl₂/MeOH) is washed with ethyl
15 ether to give 2.9 g of tetracycle.

- Yield = 72%
- ^1H NMR (CDCl_3): 3.25 (s, 3H), 4.02 (s, 3H), 7.49 (d, 1H, $J = 3.3$ Hz), 7.56 (dd, 1H, $J = 3.3$ and 9.3 Hz), 7.74 (dd, 1H, $J = 8.3$ and 4.3 Hz), 8.34 (d, 1H, $J = 9.3$ Hz), 8.71 (dd, 1H, $J = 2.5$ and 8.3 Hz), 9.12 (dd, 1H, $J = 2.5$ and 4.3 Hz).

B-7 - Synthesis of 4-(2-acetylanilino)-11-methyl-1,6-diazanaphthacene-5,12-dione (Intermediate B₇)
(CRL 8332)

Preparation according to the process described in chapter B-1: intermediate tricycle A₇ (1 g, 2.35 mmol), sulfuric acid (3.5 ml), acetic acid (18 ml). The product obtained by flash chromatography (100/30 CH₂Cl₂/MeOH) is washed with ethyl ether to give 0.6 g of tetracycle in the form of an orange powder.

- Yield = 63%
- ^1H NMR (CDCl_3): 2.59 (s, 3H), 3.25 (s, 3H), 7.29 (ddd, 1H, $J = 7.2$ and 7.2 and 1.2 Hz), 7.37 (d, 1H, $J = 6$ Hz), 7.54 (ddd, 1H, $J = 6.8$ and 6.8 and 1.6 Hz), 7.59 (d, 1H, $J = 6.8$ Hz), 7.74 (dd, 1H, $J = 7.2$ and 1.2 Hz), 7.76 (dd, 1H, $J = 6.8$ and 1.6 Hz), 7.87-7.918 (m, 2H), 8.34 (d, 1H, $J = 8.4$ Hz), 8.43 (d, 1H, $J = 8.4$ Hz), 8.54 (d, 1H, 6 Hz), 12.5 (s, 1H).

B-8 - Synthesis of 4-methoxy-9-bromo-11-methyl-1,6-diazanaphthacene-5,12-dione (Intermediate B₈)

Preparation according to the process described in chapter B-1: intermediate tricycle A₈ (1.22 g, 3.04 mmol), sulfuric acid (4.5 ml), acetic acid (27 + 23 ml). The product obtained by flash chromatography (100/3 CH₂Cl₂/MeOH) is washed with ethyl ether to give 0.76 g of tetracycle in the form of a yellow powder.

- Yield = 65%
- ¹H NMR (CDCl₃): 3.21 (s, 3H), 4.10 (s, 3H), 7.18 (d, 1H, J = 6 Hz), 7.96 (dd, 1H, J = 8.8 and 2 Hz), 8.27 (d, 1H, J = 8.8 Hz), 8.47 (d, 1H, J = 2 Hz), 8.89 (d, 1H, J = 6 Hz).

B-9 - Synthesis of 2-methoxy-11-methyl-1,6-diazanaphthacene-5,12-dione (Intermediate B₉)

A solution of 2-methoxy-6-(2-acetylphenylamino)quinoline-5,8-dione (0.34 g, 1.1 mmol) in an acetic acid/sulfuric acid mixture (25 mol/2.7 ml) is heated at 90°C for 45 minutes. After cooling, the reaction medium is poured into a water/ice mixture (200 ml) and then basified to pH 8 with K₂CO₃ and extracted with CHCl₃ (3 × 200 ml). The organic phases are dried over MgSO₄ and then concentrated on a rotary evaporator. The crude product obtained is purified by filtration on silica (CHCl₃) to give the expected tetracycle in the form of a beige-colored powder (0.23 g):

- Yield = 71%
- Melting point = 260°C
- ¹H NMR (CDCl₃): 3.32 (s, 3H), 4.23 (s, 3H), 7.14 (d, 1H, J = 8.8 Hz), 7.79 (ddd, 1H, J = 8.6, 8.4 and 1.2 Hz), 7.91 (ddd, 1H, J = 8.4, 8.6 and 1.2 Hz), 8.38 (dd, 1H, J = 8.6 and 1.2 Hz), 8.46 (dd, 1H, J = 8.4 and 1.2 Hz), 8.58 (d, 1H, J = 8.8 Hz).
- ¹³C NMR (CDCl₃): 16.63, 54.76, 117.29, 125.29, 125.50, 125.64, 129.62, 129.75, 132.37, 132.57, 138.12, 147.73, 148.63, 149.69, 152.28, 167.77, 181.10, 183.55.

- IR (CHCl₃): 1683, 1599 cm⁻¹

B-10 - Synthesis of 3-acetoxymethyl-11-methyl-1,6-diazanaphthacene-5,12-dione (Intermediate B₁₀)

5 A solution of 3-hydroxymethyl-6-(2-acetylphenylamino)-quinoline-5,8-dione (Intermediate A₁₀), (0.248 g, 0.77 mmol) in an acetic acid/sulfuric acid mixture (16 ml/1.3 ml) is heated at 90°C for 2 hours
10 30 minutes. After cooling, the reaction medium is poured into a water/ice mixture (15 ml) and then basified to pH 9 with Na₂CO₃. The medium is then extracted with CH₂Cl₂ (3 × 150 ml). The organic phases are dried over MgSO₄ and then concentrated on a rotary
15 evaporator. The crude product obtained is purified by filtration through silica (98/2 CH₂Cl₂/MeOH) to give the expected compound in the form of a brown powder (0.21 g).

- Yield = 85%

- Melting point = 210°C

20 • ¹H NMR (CDCl₃): 2.18 (s, 3H), 3.30 (s, 3H), 5.31 (s, 2H), 7.78 (ddd, 1H, J = 1.1, 6.8 and 8.1 Hz), 7.92 (ddd, 1H, J = 1.1, 6.8 and 8.1 Hz), 8.37 (dd, 1H, J = 8.1 and 1.1 Hz), 8.43 (dd, 1H, J = 8.1 and 1.1 Hz), 8.66 (d, 1H, J = 2.2 Hz), 9.09 (d, 1H, J = 2.2 Hz).

25 • ¹³C NMR (CDCl₃): 16.06, 20.11, 62.06, 124.81, 124.91, 129.06, 129.18, 129.29, 131.70, 132.18, 134.06, 136.09, 146.86, 147.97, 149.01, 152.19, 154.30, 169.72, 180.96, 182.34.

- IR (CHCl₃): 3420, 1746, 1692 cm⁻¹

30

C - Preparation of the intermediate products of formula IIIa (Scheme II)

35 1) Synthesis of N-(2,5-dimethoxyphenyl)anthranilic acid (Compound 4)

A mixture of 2-chlorobenzoic acid (9.2 g, 60 mmol), dimethoxyaniline (10 g, 65 mmol), copper (0.96 g), Cu₂O (0.96 g) and K₂CO₃ (10.4 g) in 120 ml of diglyme is

- 23 -

refluxed overnight. After evaporating off the solvent, the reaction medium is basified with 1N sodium hydroxide. Ether is added and the medium is then filtered through silica and the ether phase is removed.

5 The aqueous phase is acidified with concentrated HCl and then extracted with ethyl acetate. After drying over MgSO_4 and evaporating off the solvent on a rotary evaporator, the crude product obtained is purified by filtration through silica (CH_2Cl_2) to give the expected
10 condensation product in the form of a yellow powder (14.5 g).

- Yield = 89%
- Melting point = 138°C
- ^1H NMR (CDCl_3): 3.77 (s, 3H), 3.85 (s, 3H), 6.57
15 (dd, 1H, $J = 8.8$ and 2.9 Hz), 6.77 (ddd, 1H, $J = 1.9$ and 7.5 Hz), 6.87 (d, 1H, $J = 9.2$ Hz), 7.04 (d, 1H, $J = 2.9$ Hz), 7.3 to 7.4 (m, 2H), 9.35 (broad s, 1H)
- ^{13}C NMR (CDCl_3): 55.76, 56.45, 107.30, 107.71, 112.00, 112.26, 114.70, 117.53, 130.78, 132.60, 134.09,
20 145.98, 147.71, 153.75, 172.95
- IR (CHCl_3): $3327, 1685\text{ cm}^{-1}$

2) Synthesis of 2-(2,5-dimethoxyphenylamino)acetophenone (Compound 5)

25 16 ml of MeLi (1.4 M/ Et_2O) are added at 0°C and under N_2 to a mixture of N-(2,5-dimethoxyphenyl)anthranilic acid (2 g, 73 mmol) in 14 ml of THF. After raising the temperature, the medium is refluxed for 2 hours, 100 ml of water are then added and the mixture is extracted
30 with ether (3×100 ml). After drying over MgSO_4 , the solvent is evaporated off on a rotary evaporator to give the expected derivative in the form of a yellow solid (1.49 g).

- Yield = 75%
- 35 • Melting point = 79°C
- ^1H NMR (CDCl_3): 2.64 (s, 3H), 3.76 (s, 3H), 3.84 (s, 3H), 6.55 (dd, 1H, $J = 8.8$ and 2.9 Hz), 6.73 (dd, 1H, $J = 1.4$ and 7.5 Hz), 6.85 (d, 1H, $J = 8.8$ Hz), 7.04

- 24 -

(d, 1H, $J = 2.9$ Hz), 7.3 to 7.4 (m, 2H), 7.81 (dd, 1H, $J = 1.5$ and 8.0 Hz), 10.5 (broad s, 1H).

- ^{13}C NMR (CDCl_3): 48.15, 55.73, 56.36, 107.10, 107.72, 112.05, 114.80, 116.84, 120.09, 130.68, 132.42, 134.35, 145.98, 146.67, 153.62, 201.00
- IR (CHCl_3): 3350, 1642 cm^{-1}

3) Synthesis of 1,4-dimethoxy-9-methylacridine (Compound 6)

A mixture of 2-(2,5-dimethoxyphenylamino)acetophenone (1.3 g, 48 mmol) and polyphosphoric acid (13 g, 133 mmol) is heated at 100°C for 1 hour. After addition of 50 ml of water, the mixture is neutralized with 4M sodium hydroxide and then extracted with CHCl_3 (3 × 100 ml). After drying over MgSO_4 and evaporating off the solvent, the crude product obtained is purified by filtration through silica (CH_2Cl_2) to give the expected tricyclic derivative quantitatively in the form of a brown-orange solid.

- Melting point = 136°C
- ^1H NMR (CDCl_3): 3.36 (s, 3H), 3.96 (s, 3H), 4.09 (s, 3H), 6.68 (d, 1H, $J = 8.0$ Hz), 6.89 (d, 1H, $J = 8.4$ Hz), 7.54 (m, 1H), 7.73 (m, 1H), 8.32 (d, 1H, $J = 8.4$), 8.36 (d, 1H, $J = 8.8$ Hz)
- ^{13}C NMR (CDCl_3): 17.78, 55.66, 56.13, 102.43, 105.18, 120.25, 124.28, 125.62, 126.59, 129.44, 130.81, 142.45, 144.23, 147.21, 149.46, 151.45
- IR (CHCl_3): 1685, 1661 cm^{-1}

4) Synthesis of 9-methylacridine-1,4-dione (Compound 7)

A solution of 1,4-dimethoxy-9-methylacridine (20 mg, 0.079 mmol) and cerium ammonium nitrate (196 mg, 0.357 mmol) in a $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$ mixture (0.5 ml/0.25 ml) is stirred at 0°C for 20 minutes. After adding 1.4 ml of H_2O and 0.4 ml of saturated NaHCO_3 solution, the medium is left stirring and is then extracted with CH_2Cl_2 (3 × 3 ml). The organic phases are dried over MgSO_4 . After evaporating off the solvent on a rotary

- 25 -

evaporator, the expected quinone is obtained in the form of a brown powder (15 mg).

- Yield = 90%

- Melting point = $> 260^{\circ}\text{C}$

5 • ^1H NMR (CDCl_3): 3.22 (s, 3H), 7.09 (d, 1H, $J = 10.3$ Hz), 7.18 (d, 1H, $J = 10.3$ Hz), 7.78 (dd, 1H, $J = 8.5$ and 8.5 Hz), 7.91 (dd, 1H, 8.5 and 8.5 Hz), 8.32 (d, 1H, $J = 8.5$), 8.43 (d, 1H, $J = 8.5$ Hz).

10 • ^{13}C NMR (CDCl_3): 15.87, 124.40, 125.41, 126.30, 129.61, 132.32, 132.52, 137.88, 141.61, 147.05, 148.23, 151.23, 183.43, 186.69

- IR (CHCl_3): 1701, 1661 cm^{-1}

15 **D - Preparation of the intermediate products of formula IVa (Scheme II)**

D-1 - Synthesis of 6-methyl-1,11-diazanaphthacene-5,12-dione (Intermediate D_1)

20 A solution of 9-methylacridine-1,4-dione (200 mg, 0.896 mmol), acrolein- N,N -dimethylhydrazone (96 mg, 0.984 mmol) and acetic anhydride (1 ml) in 20 ml of CH_2Cl_2 is stirred under N_2 at room temperature for 30 minutes. After concentrating the solvent, the medium is

25 purified by filtration through silica (CH_2Cl_2) to recover the addition product that is not completely aromatic. A suspension of this compound and of 10% Pd/C (20 mg) in 4 ml of toluene is refluxed for 30 minutes. After concentrating, the crude product obtained is

30 purified by flash chromatography on silica (98/2 $\text{CH}_2\text{Cl}_2/\text{MeOH}$) to give the expected tetracycle in the form of a beige-colored powder (23 mg).

- Yield = 13%

35 • ^1H NMR (CDCl_3): 3.32 (s, 3H), 7.78-7.83 (m, 2H), 7.95 (ddd, 1H, $J = 8.4$, 7.7 and 1.5 Hz), 8.39 (dd, 1H, $J = 8.8$ and 1.5 Hz), 8.51 (dd, 1H, $J = 7.7$ and 1.5 Hz), 8.68 (dd, 1H, $J = 8.1$ and 1.9 Hz), 9.16 (dd, 1H, $J = 4.8$ and 1.9 Hz)

- 26 -

- ^{13}C NMR (CDCl_3): 16.67, 124.59, 125.44, 128.39, 129.76, 129.89, 132.25, 132.54, 132.88, 135.93, 148.00, 148.59, 148.73, 152.48, 155.31, 180.81, 184.37
- IR (CHCl_3): 1703, 1663 cm^{-1}

5

D-2 - Synthesis of 3-methoxy-6-methyl-1,11-diazanaphthacene-5,12-dione (*Intermediate D₂*)

3-Methoxy-6-methyl-1,11-diazanaphthacene-5,12-dione is prepared according to the procedure described in D-1, starting with a solution of 9-methylacridine-1,4-dione (Compound 7) (200 mg, 0.896 mmol), 2-methoxy-2-propenal-dimethylhydrazone (126 mg, 0.984 mmol) and acetic anhydride (1 ml) in 20 ml of CH_2Cl_2 .

15

EXAMPLE 1

5-Methyl-9H-quinol[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8323)

A solution of the intermediate tetracycle B₁ (1 g, 3.47 mmol) and of dimethylformamide diethyl acetal (2 ml, 10.41 mmol) in 7 ml of DMF is refluxed for 1 hour. After evaporating to dryness, ammonium chloride (2.77 g, 52 mmol) and 50 ml of ethanol are added. The reaction medium is refluxed again for 30 minutes. After evaporating off the solvent, the crude product is taken up in water and extracted 4 times with dichloromethane. The organic phases are dried over MgSO_4 and then evaporated. After recrystallization from 125 ml of methanol, 0.7 g of the expected compound CRL 8323 is obtained in the form of a mustard-yellow solid.

30

- Yield = 67%
- Melting point = 200°C
- ^1H NMR (CDCl_3): 2.69 (s, 3H), 7.65 (dd, 1H, J = 8 and 4.8 Hz), 7.81 (dd, 1H, J = 8 and 1.2 Hz), 8.44 (d, 1H, J = 1.2 Hz), 8.49 (d, 1H, J = 8 Hz), 8.50 (d, 1H, J = 5.6 Hz), 8.78 (dd, 1H, J = 2 and 8 Hz), 9.15 (dd, 1H, J = 4.8 and 2 Hz), 9.24 (d, 1H, J = 5.6 Hz)
- ^{13}C NMR (CDCl_3): 22.06, 116.54, 117.87, 122.15, 123.12, 125.24, 128.74, 132.58, 133.47, 136.25, 137.19,

35

- 27 -

141.63, 143.88, 144.79, 149.16, 149.31, 152.09, 155.15, 181.53

• MS (m/z): 297 (17.6), 296 (34.3), 268 (25.4), 149 (50.3)

5

EXAMPLE 2

5-Chloro-9H-quinol[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8301)

Preparation according to the process described in Example 1, starting with the intermediate tetracycle B₂ (0.25 g, 0.81 mmol) and dimethylformamide diethyl acetal (1.5 ml, 8.75 mmol) in DMF (4.5 ml). Ammonium chloride (2.95 g, 55 mmol), ethanol (50 ml). After purification by flash chromatography (98/2 CH₂Cl₂/MeOH), 60 mg of the expected compound CRL 8301 are obtained in the form of a yellow solid.

- Yield = 23%
- Melting point = 200°C
- ¹H NMR (CDCl₃): 7.68 (dd, 1H, J = 8.4 and 4.8 Hz), 7.94 (dd, 1H, J = 8.8 and 2 Hz), 8.46 (d, 1H, J = 5.6 Hz), 8.55 (d, 1H, J = 8.8 Hz), 8.63 (d, 1H, J = 2 Hz), 8.79 (dd, 1H, J = 2 and 8.4 Hz), 9.18 (dd, 1H, J = 4.8 and 2 Hz), 9.30 (d, 1H, J = 5.6 Hz)
- ¹³C NMR (CDCl₃): 117.07, 118.46, 122.98, 124.82, 126.12, 129.34, 133.02, 134.81, 137.00, 137.42, 137.79, 144.45, 146.35, 150.24, 150.45, 152.55, 156.02, 181.9
- MS (m/z): 319 (43), 317 (100), 291 (14.5), 290 (18), 289 (100).

EXAMPLE 3

5-(Benzylamino)-9H-quinol[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8241)

Preparation according to the process described in Example 1, starting with the intermediate tetracycle B₃ (3.58 g, 9.45 mmol) and dimethylformamide diethyl acetal (5.7 ml, 33.26 mmol) in DMF (19 ml). Ammonium chloride (2.95 g, 55 mmol), ethanol (50 ml). After purification by flash chromatography (96/4 CH₂Cl₂/MeOH),

2 g of the expected compound CRL 8241 are obtained in the form of a wine-colored powder.

- Yield = 55%
- Melting point = 219°C
- 5 • ¹H NMR (CDCl₃): 4.61 (d, 2H), 5.10 (t, 1H), 7.31 (dd, 1H, J = 8.8 Hz, J = 2.4 Hz), 7.452-7.327 (m, 5H), 7.55 (d, 1H, J = 2.4 Hz), 7.63 (dd, 1H, J = 4.4 Hz, J = 8.4 Hz), 8.29 (d, 1H, J = 5.2 Hz), 8.36 (d, 1H, J = 8.8 Hz), 8.79 (dd, 1H, J = 1.2 Hz, J = 8.4 Hz), 9.13 (dd, 1H, J = 4.4 and 1.2 Hz), 9.14 (d, 1H, J = 5.2 Hz)
- 10 • MS (m/z): 388 (7), 387 (100), 386 (85), 385 (25), 369 (99), 368 (44)

EXAMPLE 4

- 15 **5-(Dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8325)**

Preparation according to the process described in Example 1, starting with the intermediate tetracycle B₅ (0.25 g, 0.79 mmol) and dimethylformamide diethyl acetal (0.5 ml, 2.98 mmol) in DMF (5 ml). Ammonium chloride (1 g, 18.7 mmol), ethanol (16 ml). After purification by flash chromatography (100/5 CH₂Cl₂/MeOH), 170 mg of the expected compound CRL 8325 are obtained in the form of a violet powder.

- 25 • Yield = 66%
- Melting point = > 260°C
- ¹H NMR (CDCl₃): 3.25 (s, 6H), 7.45 (dd, 1H, J = 9.2 Hz, J = 3 Hz), 7.57 (d, 1H, J = 3 Hz), 7.63 (dd, 1H, J = 4.4 and 8 Hz), 8.41 (d, 1H, J = 9.2 Hz), 8.43 (d, 1H, J = 5.6 Hz), 8.81 (dd, 1H, J = 2 and 7.6 Hz), 9.13 (dd, 1H, J = 4.4 and 2 Hz), 9.17 (d, 1H, J = 5.6 Hz)
- 30 • ¹³C NMR (CDCl₃): 40.45, 100.84, 116.81, 118.69, 118.99, 125.19, 126.10, 129.46, 134.62, 136.03, 136.30, 139.00, 140.69, 148.16, 149.15, 151.53, 152.47, 154.83, 181.65
- 35 • MS (m/z): 326 (34.5), 325 (100), 324 (100), 254 (15.5), 253 (13.4).

EXAMPLE 5

**5-Methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one
(CRL 8297)**

Preparation according to the process described in
5 Example 1, starting with the intermediate tetracycle B₆
(2 g, 6.57 mmol) and dimethylformamide diethyl acetal
(4 ml, 23.34 mmol) in DMF (14 ml). Ammonium chloride
(8 g, 149.5 mmol), ethanol (130 ml). After purification
by flash chromatography (100/5 CH₂Cl₂/MeOH), 170 mg of
10 the expected compound CRL 8297 are obtained in the form
of a greenish solid.

- Yield = 66%
- Melting point = > 260°C
- ¹H NMR (CDCl₃): 4.10 (s, 3H), 7.62 (dd, 1H, J =
15 9.2 Hz, J = 2.4 Hz), 7.66 (dd, 1H, J = 4.4 and 8 Hz),
7.96 (d, 1H, J = 2.4 Hz), 8.48 (d, 1H, J = 2.4 Hz),
8.54 (d, 1H, J = 9.2 Hz), 8.80 (dd, 1H, J = 2.4 and
8 Hz), 9.16 (dd, 1H, J = 4.4 and 2.4 Hz), 9.25 (d, 1H,
J = 5.2 Hz)
- 20 • ¹³C NMR (CDCl₃): 30.93, 116.86, 118.41, 122.44,
125.56, 129.25, 134.96, 136.55, 137.13, 141.52, 143.67,
149.11, 149.77, 152.37, 155.38, 161.71, 181.93, 207.00
- MS (m/z): 313 (26), 312 (100), 285 (2), 284
(15), 269 (15), 242 (32.5).

25

EXAMPLE 6

**7-Nitro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one
(CRL 8289)**

Ascididemin (2 g, 7.06 mmol) is added portionwise to a
30 mixture of 45 ml of sulfuric acid and 45 ml of nitric
acid at 0°C. The reaction medium is heated at 130°C for
2 hours and, after cooling, is then poured into a
conical flask containing 400 g of ice. After
filtration, a yellow precipitate is obtained, which is
35 rinsed several times with ether. It is then taken up in
a 600/1/300 CH₂Cl₂/NH₄OH/H₂O mixture. The organic phase
is recovered and the aqueous phase is extracted 3 times
with CH₂Cl₂. After drying over MgSO₄, the organic phases

- 30 -

are evaporated to give 1.62 g of the expected compound CRL 8289 in the form of a yellow solid.

- Yield = 70%

- Melting point = 224°C

5 • ¹H NMR (CDCl₃): 7.69 (dd, 1H, J = 4.4 and 8 Hz),
8.04 (dd, 1H, J = 8 and 8 Hz), 8.28 (dd, 1H, J = 8 Hz),
8.56 (d, 1H, J = 5.2 Hz), 8.75 (dd, 1H, J = 2 and 8
Hz), 8.89 (dd, 1H, J = 1.2 and 8 Hz), 9.18 (dd, 1H, J =
4.4 and 2 Hz), 9.37 (d, 1H, J = 5.6 Hz)

10 • ¹³C NMR (CDCl₃): 79.20, 117.61, 118.39, 124.21,
124.89, 125.98, 127.54, 129.04, 130.14, 135.62, 136.63,
148.17, 149.76, 149.94, 150.12, 151.66, 154.88, 180.56.

- MS (m/z): 328 (18), 327 (100), 299 (22), 297
(9), 269 (10), 253 (24), 242 (11), 241 (33).

15

EXAMPLE 7

7-Amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8344)

A suspension of the nitro derivative CRL 8289 (0.4 g,
20 1.22 mmol) and iron (0.37 g, 6.59 mmol) in a 10/10
AcOH/H₂O mixture is refluxed for 1 hour. EDTA (1.94 g,
6.59 mmol) is added and the reaction medium is then
basified with concentrated sodium hydroxide. The
mixture is extracted 3 times with CH₂Cl₂. After drying
25 over MgSO₄, the organic phases are evaporated to give
0.32 g of the expected compound CRL 8344 in the form of
a blue solid.

- Yield = 88%

- Melting point = > 260°C

30 • ¹H NMR (CDCl₃): 5.68 (s, 2H), 7.16 (d, 1H, J =
7.8 Hz), 7.66 (dd, 1H, J = 7.6 and 4.8 Hz), 7.69 (dd,
1H, J = 7.8 and 7.8 Hz), 7.91 (d, 1H, J = 7.8 Hz), 8.46
(d, 1H, J = 5.2 Hz), 8.77 (dd, 1H, J = 1.6 and 7.6 Hz),
9.17 (dd, 1H, J = 1.6 and 4.8 Hz), 9.21 (d, 1H, J =
35 5.2 Hz).

- ¹³C NMR (CDCl₃): 109.42, 112.71, 117.70, 118.43,
124.29, 125.64, 129.12, 132.63, 132.81, 135.53, 137.27,
141.68, 148.68, 148.89, 149.03, 151.96, 154.68, 180.71

- 31 -

• MS (m/z): 298 (34.7), 297 (100), 269 (11), 268 (8).

EXAMPLE 8

5 5-Bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8248)

A solution of bromine (0.2 ml, 3.88 mmol) in 5 ml of acetic acid is added dropwise to a solution of ascididemin (0.5 g, 1.77 mmol) in 20 ml of acetic acid.
10 The reaction medium is refluxed (stoppered condensor) for 24 hours. After cooling, the mixture is neutralized with saturated NaHCO₃ solution and extracted 4 times with CH₂Cl₂. The organic phases are dried over MgSO₄ and then evaporated. The crude product obtained is purified
15 by flash chromatography on a column of silica (96/4 CH₂Cl₂/MeOH) to give 0.548 g of the expected compound CRL 8248 in the form of a yellow solid.

- Yield = 86%
- Melting point = 208°C
- 20 • ¹H NMR (CDCl₃): 7.68 (dd, 1H, J = 4.4 and 8 Hz), 8.09 (dd, 1H, J = 8.8 Hz, J = 2 Hz), 8.48 (d, 1H, J = 8.8 Hz), 8.49 (d, 1H, J = 6 Hz), 8.79 (dd, 1H, J = 2 and 8 Hz), 8.82 (d, 1H, J = 2 Hz), 9.18 (dd, 1H, J = 2 Hz, J = 4.4 Hz), 9.30 (d, 1H, J = 6 Hz)
- 25 • ¹³C NMR (CDCl₃): 116.76, 117.04, 118.26, 124.76, 125.81, 125.93, 129.05, 134.52, 135.43, 136.72, 137.01, 144.41, 146.24, 149.93, 150.12, 152.27, 155.67, 181.69
- MS (m/z): 363 (99), 362 (83), 361 (100), 360 (27), 255 (9), 254 (51).

30

EXAMPLE 9

5-Amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8347)

Sodium azide (2.34 g, 36.1 mmol) is added to a solution
35 of bromo ascididemin: CRL 8248 (2.3 g, 6.33 mmol) in 460 ml of DMF. The reaction medium is refluxed for 4 hours. After cooling, the mixture is evaporated to dryness and the solid obtained is taken up in water. This mixture is extracted 4 times with CH₂Cl₂. After

drying over MgSO_4 and evaporating off the solvent, the crude product is purified by flash chromatography on a column of silica (90/10 $\text{HCCl}_3/\text{MeOH}$) to give 115 mg of the expected compound CRL 8347 in the form of a black powder.

- Yield = 6%
- Melting point = > 260°C
- ¹H NMR (CDCl₃): 7.43 (dd, 1H, J = 8.8 and 2.4 Hz), 7.74 (dd, 1H, J = 4.8 and 8 Hz), 7.81 (d, 1H, J = 2.4 Hz), 8.48 (d, 1H, J = 6 Hz), 8.50 (d, 1H, J = 8.8 Hz), 8.90 (dd, 1H, J = 2 and 8 Hz), 9.25 (dd, 1H, J = 2 and 4.8 Hz), 9.29 (d, 1H, J = 6 Hz)
- ¹³C NMR (DMSO): 102.26, 117.13, 118.54, 121.62, 123.20, 125.34, 126.11, 129.18, 133.80, 134.83, 135.47, 138.42, 147.65, 148.29, 151.63, 152.39, 154.32, 180.35
- MS (m/z): 298 (32), 297 (100), 269 (4), 268 (0.5)

EXAMPLE 10

20 10-Methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one
(CRL 8368)

Preparation according to the procedure described by Y. Kitahara et al., *Heterocycles*, 1993, 36, 943-946.

25 **EXAMPLE 11**

10-Hydroxy-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one
(CRL 8387)

Preparation according to the procedure described by Y. Kitahara et al., Tetrahedron, 1997, 53, 17029-17038.

EXAMPLE 12

9H-Quino[4,3,2-de][1,10]phenanthrolin-9-imine
(CRL 8290)

100 mg (0.353 mmol) of ascididemin are dissolved in a
35 solution containing 5 ml of aqueous ammonia and 2 ml of
EtOH. The reaction medium is refluxed (stoppered
condensor) for 72 hours. After evaporating off the
solvent on a rotary evaporator, the residue is purified

- Yield = 87%
- Melting point = > 260°C

- 5 • ^1H NMR (CDCl_3): 7.61 (dd, 1H, $J = 5$ and 8 Hz),
7.86 (dd, 1H, $J = 8$ and 8 Hz), 7.97 (dd, 1H, $J = 8$ and
8 Hz), 8.40 (d, 1H, $J = 8$ Hz), 8.43 (d, 1H, $J = 6$ Hz),
8.64 (d, 1H, $J = 8$ Hz), 9.04 (dd, 1H, $J = 8$ and
2.5 Hz), 9.08 (dd, 1H, $J = 5$ and 2.5 Hz), 9.22 (d, 1H,
10 $J = 6$ Hz), 12.48 (s, 1H)

9H-Quino[4,3,2-de][1,10]phenanthrolin-9-oxime
(CRL 8292)

500 mg (1.77 mmol) of ascididemin and 500 mg of NH_2OH , $1/2 \text{ H}_2\text{SO}_4$ are dissolved in 1 ml of pyridine and 10 ml of EtOH. The reaction medium is refluxed for 48 hours. After evaporating off the solvent on a rotary evaporator, 20 ml of water are added and the medium is extracted with HCCl_3 ($3 \times 20 \text{ ml}$). The organic phases are dried over MgSO_4 and then evaporated on a rotary evaporator. The residue is purified by flash chromatography on alumina (99/1 $\text{CH}_2\text{Cl}_2/\text{MeOH}$) to give 240 mg of the oxime CRL 8292 in the form of a yellow powder.

- Yield = 46%
- Melting point = > 260°C
- ¹H NMR (CDCl₃): 7.68 (dd, 1H, J = 4.4 and 8.4 Hz), 7.98 (ddd, 1H, J = 7.6 and 7.6 and 1.6 Hz), 8.07 (ddd, 1H, J = 7.6 and 7.6 and 1.6 Hz), 8.30 (dd, 1H, J = 7.6 and 1.6 Hz), 8.56 (d, 1H, J = 6 Hz), 8.75 (dd, 1H, J = 7.6 and 1.6 Hz), 9.00 (dd, 1H, J = 8.4 and 1.2 Hz), 9.12 (dd, 1H, J = 4.4 and 1.2 Hz), 9.41 (d, 1H, J = 6 Hz)
- ¹³C NMR (CDCl₃): 115.06, 116.14, 123.16, 123.29, 125.46, 128.33, 128.77, 129.54, 131.86, 132.16, 138.48, 140.94, 141.37, 145.82, 146.75, 151.27, 151.65, 151.80
- MS (m/z): 298 (64.5), 268 (100), 266 (21.9)

1.

(CRL 8333)

- Yield = 35%

- Melting point = $> 260^{\circ}\text{C}$

• ^{13}C NMR (CDCl_3): 37.22, 45.05, 109.94, 113.94.

30 **EXAMPLE 15**

(CRL 8369)

500 mg (1.597 mmol) of the compound of Example 10
35 (CRL 8368) and 40 ml of acetic acid in 100 ml of
hydriodic acid (57%) are heated at 100°C for 30
minutes. After cooling, the reaction medium is poured
into 500 ml of water and ice is added, followed by
neutralization with NaHCO₃ (solid). After several

extractions with a mixture of 5% MeOH in HCCl_3 (6 times 500 ml), the organic phases are dried over MgSO_4 and then concentrated on a rotary evaporator to give 0.36 g of compound CRL 8369 in the form of a wine-colored powder.

- Yield = 41%
- Melting point = $> 260^\circ\text{C}$
- ^1H NMR (DMSO): 6.24 (d, 1H, $J = 7.6$ Hz), 6.86 (td, 1H, $J = 8$ and 4 Hz), 7.27 (d, 2H, $J = 4$ Hz), 7.57 (d, 1H, $J = 5.2$ Hz), 7.89 (d, 1H, $J = 8$ Hz), 7.93 (dd, 1H, $J = 7.6$ and 7.6 Hz), 8.51 (d, 1H, $J = 5.2$ Hz), 9.54 (s, 1H), 12.62 (broad m, 1H), 14.42 (s, 1H)
- ^{13}C NMR (DMSO): 107.81, 109.87, 114.24, 115.36, 116.31, 117.33, 120.11, 120.97, 124.14, 127.63, 132.18, 132.81, 134.89, 139.24, 139.35, 141.15, 148.72, 181.29

EXAMPLE 16

10-Chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8373)

50 mg (0.09 mmol) of the salt of Example 15 (CRL 8369) dissolved in 4 ml of POCl_3 are refluxed for 2 hours. After evaporating off the POCl_3 on a rotary evaporator, the reaction medium is neutralized with saturated NaHCO_3 solution. After several extractions with a mixture of 5% MeOH in HCCl_3 (5 times 20 ml), the organic phases are dried over MgSO_4 and then concentrated on a rotary evaporator. The residue obtained is purified by flash chromatography on a column of silica (95/5 $\text{CH}_2\text{Cl}_2/\text{MeOH}$) to give 20 mg of the expected compound CRL 8373 in the form of a yellow powder.

- Yield = 77%
- Melting point = $> 260^\circ\text{C}$
- ^1H NMR (CDCl_3): 7.67 (d, 1H, $J = 5.6$ Hz), 7.95 (ddd, 1H, $J = 8$ and 8 and 0.8 Hz), 8.03 (ddd, 1H, $J = 8$ and 8 and 1.2 Hz), 8.57 (d, 1H, $J = 5.6$ Hz), 8.61 (ddd, 1H, $J = 8$ and 1.2 Hz), 8.68 (ddd, 1H, $J = 8$ and 0.8 Hz), 8.97 (d, 1H, $J = 5.6$ Hz), 9.30 (d, 1H, $J = 5.6$ Hz)

• ^{13}C NMR (CDCl_3): 117.60, 117.84, 123.31, 123.60, 126.69, 129.10, 131.17, 132.38, 133.47, 138.21, 146.24, 146.51, 147.26, 149.40, 150.32, 154.30, 154.94, 180.47

• MS (m/z): 318 (9.6), 316 (70.2), 290 (29.6), 288 (100), 255 (23.4), 253 (26.8).

EXAMPLE 17

5-Bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one

10 (CRL 8389)

Preparation according to the process described in Example 1, starting with the intermediate tetracycle B₈ (0.74 g, 1.93 mmol) and dimethylformamide diethyl acetal (1.3 ml, 7.24 mmol) in 15 ml of DMF. Ammonium chloride (1.96 g, 36.4 mmol), ethanol (200 ml). After purification by flash chromatography (95/5 $\text{CH}_2\text{Cl}_2/\text{MeOH}$), 210 mg of the expected compound CRL 8389 are obtained in the form of an orange powder.

• Yield = 42%

20 • Melting point = $> 260^\circ\text{C}$

• ^1H NMR (CDCl_3): 4.14 (s, 3H), 7.14 (d, 1H, $J = 5.6$ Hz), 8.05 (dd, 1H, $J = 2$ and 8.8 Hz), 8.43 (d, 1H, $J = 6$ Hz), 8.44 (d, 1H, $J = 8.8$ Hz), 8.76 (d, 1H, $J = 2$ Hz), 8.95 (d, 1H, $J = 6$ Hz), 9.27 (d, 1H, $J = 5.6$ Hz)

25 • ^{13}C NMR (CDCl_3): 57.12, 109.52, 117.00, 117.76, 119.46, 121.58, 124.81, 125.52, 134.72, 135.49, 137.00, 144.85, 146.51, 147.24, 147.92, 150.43, 156.21, 167.98, 180.57

30 • MS (m/z): 393 (100), 392 (61.7), 391 (99.2), 390 (17.4), 362 (9.2), 333 (9.8), 254 (34.5).

EXAMPLE 18

5-Amino-11-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one

35 (CRL 8389)

A solution of compound CRL 8389 (0.5 g, 1.3 mmol) and NaN_3 (0.5 g, 7.7 mmol) in 20 ml of DMF is heated at 90°C for 10 hours. After concentrating, the residue is

taken up in 1N KOH (35 ml) and then extracted with 95/5 CH₂Cl₂/MeOH (4 × 200 ml). After drying over MgSO₄ and concentrating on a rotary evaporator, the crude product obtained is purified by flash chromatography on silica (80/20 CH₂Cl₂/MeOH) to give the expected compound CRL 8389 in the form of a violet powder (65 mg).

- Yield = 15%
- Melting point = > 260°C
- ¹H NMR (DMSO-d₆): 4.07 (s, 3H), 6.62 (s, 2H), 7.36 (d, 1H, J = 8.8 Hz), 7.41 (d, 1H, J = 5.9 Hz), 7.74 (s, 1H), 8.08 (d, 1H, J = 8.8 Hz), 8.48 (d, 1H, J = 5.2 Hz), 8.86 (d, 1H, J = 5.9 Hz), 9.08 (d, 1H, J = 5.2 Hz)
- IR (KBr): 3420, 3196, 1636, 1616 cm⁻¹

EXAMPLE 19

5-Amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one hydrochloride (CRL 8406)

A solution of 5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (1 g, 3.35 mmol) and concentrated HCl (0.56 ml) in 200 ml of methanol is stirred at room temperature for 1 hour. 200 ml of ether are added and, after leaving the salt to precipitate out, the medium is filtered to recover the expected compound CRL 8406 in the form of a black powder (1 g).

- Yield = 90%
- ¹H NMR (DMSO-d₆): 7.44 (dd, 1H, J = 8.8 and 2.2 Hz), 7.81 (d, 1H, J = 2.2 Hz), 7.93 (dd, 1H, J = 5.6 and 5.9 Hz), 8.12 (d, 1H, J = 8.8 Hz), 8.66 (d, 1H, J = 5.6 Hz), 8.75 (d, 1H, J = 5.9 Hz), 9.07 (d, 1H, J = 5.9 Hz), 9.14 (d, 1H, J = 5.9 Hz)
- IR (KBr): 3404, 3287, 3170, 1691, 1676, 1649 cm⁻¹

EXAMPLE 20

5-(Dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one hydrochloride (CRL 8407)

A solution of 5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (1 g, 3.06 mmol) and

- 38 -

concentrated HCl (0.3 ml) in 120 ml of CHCl₃ is stirred at room temperature for 45 minutes. After addition of 350 ml of ether, followed by precipitation of the salt, the medium is filtered to recover the expected product in the form of a navy blue powder (0.97 g).

- Yield = 87%
- Melting point = > 260°C

EXAMPLE 21

10 5-(Benzylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one hydrochloride (CRL 8416)

A solution of 5-(benzylamino)-9H-quino[4,3,2-de][1,10]-phenanthrolin-9-one ASC20 (0.94 g, 2.42 mmol) and concentrated HCl (0.2 ml) in 40 ml of CHCl₃ is stirred at room temperature for 30 minutes. The solvent is evaporated off and 150 ml of ether are added and, after leaving the salt to precipitate out, the medium is filtered to recover the expected compound CRL 8416 in the form of a black powder (0.98 g).

- 20
- Yield = 95%
 - Melting point = > 260°C

EXAMPLE 22

25 5-(Dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one (CRL 8419)

25 ml (166 mmol) of trifluoroacetic acid are added to a mixture of compound CRL 8347 (2.56 g, 8.59 mmol) and dimethylformamide diethyl acetal (7.9 ml, 43.3 mmol) at 0°C. The reaction medium is stirred for 5 minutes and sodium cyanoborohydride (8.2 g, 130 mmol) is then added portionwise. The reaction medium is then heated and maintained at 95°C. After 18 hours, the mixture is basified to pH 8 with saturated NaHCO₃ solution (about 600 ml) and then extracted with 95/5 CHCl₃/MeOH (3 × 800 ml). The organic phases are washed with water and then dried over MgSO₄. After evaporating off the solvent on a rotary evaporator, the crude product obtained is purified by filtration through alumina (CHCl₃ and then 95 CHCl₃/MeOH) to give 1.15 g of the

- 39 -

expected compound CRL 8419 in the form of a black powder.

- Yield = 36%
- Melting point: decomposes before melting
- 5 • ^1H NMR (CDCl_3): 2.37 (s, 6H), 2.62 (t, 2H, $J = 7.32$ Hz), 3.70 (t, 2H, $J = 7.32$ Hz), 7.39 (dd, 1H, $J = 9.2$ and 3 Hz), 7.62 (dd, 1H, $J = 8.0$ and 4.5 Hz), 7.66 (d, 1H, $J = 3$ Hz), 8.35 (d, 1H, $J = 9.2$ Hz), 8.38 (d, 1H, $J = 5.7$ Hz), 8.79 (dd, 1H, $J = 8.0$ and 1.8 Hz),
10 9.12 (dd, 1H, $J = 4.5$ and 1.8 Hz), 9.15 (d, 1H, $J = 5.7$ Hz)
- ^{13}C NMR (CDCl_3): 45.97, 50.31, 56.40, 101.05, 116.81, 118.48, 118.89, 125.22, 126.30, 129.35, 134.87, 135.97, 136.32, 138.91, 140.55, 148.25, 148.98, 149.69,
15 152.23, 154.82, 181.37
- IR (CHCl_3): 1663 cm^{-1}
- MS (m/z): 369 (100), 354 (15), 236 (37)

EXAMPLE 23

20 5-(Dimethylamino-2-ethyl)amino-9H-quinol[4,3,2-de][1,10]phenanthrolin-9-one hydrochloride (CRL 8418)
265 μl (3.25 mmol) of concentrated hydrochloric acid are added to 1.2 g (3.25 mmol) of compound CRL 8419 dissolved in 60 ml of chloroform. The reaction medium
25 is stirred for 2 hours at room temperature. The precipitate formed is filtered off and then washed with ether. Compound CRL 8418 (0.93 g) is obtained in the form of a black powder.

- Yield = 70%
- 30 • ^1H NMR ($\text{DMSO}-d_6$): 2.67 (s, 6H), 3.09 (m, 2H), 4.01 (m, 2H), 7.67 (dm, 1H, $J = 9.2$ Hz), 7.80 (dd, 1H, $J = 8.0$ and 4.5 Hz), 7.94 (m, 1H), 8.26 (d, 1H, $J = 9.2$ Hz), 8.64 (d, 1H, $J = 5.7$ Hz), 9.09 (m, 1H), 9.12 (dd, 1H, $J = 4.5$ and 1.8 Hz), 9.14 (d, 1H, $J = 5.7$ Hz).

35

EXAMPLE 24

5-Bis(2-chloroethyl)amino-9H-quinol[4,3,2-de][1,10]-phenanthrolin-9-one
(CRL 8422)

- 40 -

10 mmol of sodium cyanoborohydride NaBH_3CN (0.63 g) are added portionwise to a solution of 5-amino-9H-quino-[4,3,2-de][1,10]phenanthrolin-9-one (1 g, 3.95 mmol) and chloroacetaldehyde (50% aqueous, 2.6 ml, 16.8 mmol) in acetic acid (30 ml), at 0°C. The reaction medium is stirred at 0°C for 5 minutes and then at room temperature for 30 minutes. Next, the medium is basified with saturated sodium hydrogen carbonate NaHCO_3 solution and then extracted with a 95/5 $\text{CHCl}_3/\text{MeOH}$ mixture. The organic phases are dried over magnesium sulfate MgSO_4 and concentrated on a rotary evaporator. The crude product obtained is purified by filtration through silica (CHCl_3 and then 99/1 $\text{CHCl}_3/\text{MeOH}$) to give two compounds: CRL 8422 and CRL 8423 (described in Example 25).

5-Bis(chloroethyl)amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8422) was obtained in the form of a pink powder (0.14 g):

- Yield = 10%
- Melting point = 220°C
- IR (KBr): 1666, 1650 cm^{-1}
- ^1H NMR (CDCl_3): 3.83 (t, 4H, $J = 7.0$ Hz), 4.04 (t, 4H, $J = 7.0$ Hz), 7.47 (dd, 1H, $J = 9.5$ and 2.9 Hz), 7.66 (dd, 1H, $J = 8.0$ and 4.4 Hz), 7.70 (d, 1H, $J = 2.9$ Hz), 8.42 (d, 1H, $J = 5.6$ Hz), 8.50 (d, 1H, $J = 9.5$ Hz), 8.81 (dd, 1H, $J = 8.0$ and 1.8 Hz), 9.16 (dd, 1H, $J = 4.4$ and 1.8 Hz), 9.23 (d, 1H, $J = 5.6$ Hz)
- ^{13}C NMR (CDCl_3): 40.16, 53.60, 101.70, 116.60, 118.37, 118.68, 125.39, 125.91, 129.25, 135.13, 136.12, 136.38, 139.42, 141.93, 148.24, 148.73, 149.34, 152.22, 155.08, 181.43.

EXAMPLE 25

5-(2-chloroethyl)amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8423)

According to the process described in Example 24, 0.22 g of compound CRL 8423 are obtained in the form of

- 41 -

a violet powder. The characteristics of compound CRL 8423 are as follows:

- Yield = 18%
- Melting point = 196°C
- 5 • IR (KBr): 3413, 3275, 1654, 1617 cm^{-1}
- ^1H NMR (CDCl_3): 3.81 (t, 2H, $J = 5.5$ Hz), 3.88 (t, 2H, $J = 5.5$ Hz), 5.01 (broad s, 1H), 7.34 (dd, 1H, $J = 8.8$ and 2.5 Hz), 7.60 (d, 1H, $J = 2.5$ Hz), 7.65 (dd, 1H, $J = 7.5$ and 4.4 Hz), 8.41 (d, 1H, $J = 5.8$ Hz), 10 8.43 (d, 1H, $J = 8.8$ Hz), 8.82 (dd, 1H, $J = 7.5$ and 1.5 Hz), 9.15 (dd, 1H, $J = 4.4$ and 1.5 Hz), 9.21 (dd, 1H, $J = 5.8$ Hz)
- ^{13}C NMR (CDCl_3): 42.83, 45.01, 100.76, 116.81, 118.78, 120.85, 125.38, 126.35, 129.35, 135.04, 136.04, 15 136.43, 140.22, 141.56, 148.49 (2C), 149.41, 152.30, 155.07, 181.57.

EXAMPLE 26

20 **12-Methoxy-9-*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one (CRL 8472)**

0.54 ml (3 mmol) of dimethylformamide diethyl acetal is added to a suspension of 2-methoxy-11-methyl-1,6-diazanaphthacene-5,12-dione (*Intermediate B₉*) (0.23 g, 0.75 mmol) in DMF (7 ml) under N_2 . The reaction medium is heated at 120°C for 1 hour. After concentrating under vacuum, ethanol (45 ml) and NH_4Cl (0.46 g) are added and the mixture is then refluxed for 30 minutes. After concentrating on a rotary evaporator, 30 ml of water are added and the medium is then extracted with 30 CHCl_3 (2 \times 30 ml). The organic phases are dried over MgSO_4 and concentrated. The crude product obtained is purified by flash chromatography on silica (CHCl_3) to give the expected compound CRL 8472 in the form of a brown powder (50 mg).

- 35 • Yield = 21%
- Melting point = > 260°C
- ^1H NMR (CDCl_3): 4.31 (s, 3H), 7.04 (d, 1H, $J = 8.5$ Hz), 7.92 (ddd, 1H, $J = 8.1$, 7.0 and 1.5 Hz), 8.00 (ddd, 1H, $J = 8.4$, 7.0 and 1.5 Hz), 8.52 (d, 1H, $J =$

- 42 -

5.5 Hz), 8.63 (dd, 1H, J = 8.1 and 1.5 Hz), 8.66 (d, 1H, J = 8.5 Hz), 8.67 (dd, 1H, J = 8.4 and 1.5 Hz), 9.27 (d, 1H, J = 5.5 Hz)

- ^{13}C NMR (CDCl_3): 54.69, 114.43, 116.75, 118.15, 122.92, 123.41, 124.51, 130.62, 131.81, 133.15, 137.86, 139.17, 145.80, 146.28, 149.59, 149.99, 152.24, 167.75, 181.04
- IR (CHCl_3): 1671, 1588 cm^{-1}
- MS (m/z): 313 (50), 312 (91), 284 (17), 283 (100), 254 (23), 193 (51).

EXAMPLE 27

4-Bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8478)

15 Bromine (35 μl , 0.67 mmol) is added to a suspension of compound CRL 8347 (0.2 g, 0.67 mmol) in acetic acid (8 ml). The reaction medium is heated at 50°C for 6 hours. After concentrating, the medium is basified with 5N sodium hydroxide (20 ml) and then extracted with a 20 5% MeOH/ CHCl_3 mixture (400 ml). After drying over MgSO_4 and evaporating off the solvent, compound CRL 8478 is obtained in the form of a violet powder which is recrystallized from a 20 ml/15 ml CHCl_3 /pentane mixture (152 mg).

- 25 • Yield = 61%
- Melting point = > 260°C
- ^1H NMR ($\text{DMSO}-d_6$): 7.07 (broad s, 2H), 7.61 (d, 1H, J = 8.8 Hz), 7.77 (dd, 1H, J = 7.7 and 4.0 Hz), 8.18 (d, 1H, J = 8.8 Hz), 8.61 (d, 1H, J = 7.7 Hz), 30 9.10 (d, 1H, J = 4.0 Hz), 9.14 (d, 1H, J = 5.9 Hz), 9.91 (d, 1H, J = 5.9 Hz)
- IR (CHCl_3): 3501, 3400, 1673 cm^{-1}
- MS (m/z): 378 (42), 377 (100), 376 (48), 375 (27)

35

EXAMPLE 28

11-Acetoxymethyl-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one (CRL 8528)

Dimethylformamide diethyl acetal (0.27 ml, 1.5 mmol) is added to a suspension of 3-acetoxymethyl-11-methyl-1,6-diazanaphthacene-5,12-dione (*Intermediate B₁₀*) (0.11 g, 0.31 mmol) in DMF (4 ml) under N₂. The reaction medium is heated at 120°C for 1 hour. After concentrating under vacuum, ethanol (25 ml) and NH₄Cl (0.23 g) are added and the mixture is then refluxed for 30 minutes. After concentrating on a rotary evaporator, 30 ml of water are added and the medium is then extracted with CHCl₃ (2 × 30 ml). The organic phases are dried over MgSO₄. After evaporating off the solvent on a rotary evaporator and purification by flash chromatography on silica (CHCl₃), 65 mg of compound CRL 8528 are obtained.

- Yield = 60%
- Melting point = 206-210°C
- ¹H NMR (CDCl₃): 2.19 (s, 3H), 5.32 (s, 2H), 7.96 (ddd, 1H, J = 1, 1.8 and 8 Hz), 8.03 (ddd, 1H, J = 1, 1.8 and 8.4 Hz), 8.56 (d, 1H, J = 5.5 Hz), 8.64 (dd, 1H, J = 1.1 and 8.4 Hz), 8.71 (dd, 1H, J = 1.1 and 8.0 Hz), 8.77 (d, 1H, J = 2.4 Hz), 9.14 (d, 1H, J = 2.4 Hz), 9.28 (d, 1H, J = 5.5 Hz)
- MS (m/z): 355 (88), 313 (100), 296 (25), 267 (7).

EXAMPLE 29

9-H-Quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8529)

Dimethylformamide diethyl acetal (0.15 ml, 0.875 mmol) is added to a suspension of 6-methyl-1,11-diazanaphthacene-5,12-dione (*Intermediate D₁*) (52 mg, 0.875 mmol) under N₂. The reaction medium is heated at 120°C for 30 minutes. After concentrating under vacuum, ethanol (60 ml) and NH₄Cl (0.34 g) are added and the mixture is refluxed for 30 minutes. After concentrating on a rotary evaporator, 10 ml of water are added and the medium is then extracted with CH₂Cl₂ (2 × 10 ml). The organic phases are dried over MgSO₄ and concentrated. The crude product obtained is purified by flash chromatography on silica (99/1 CH₂Cl₂/MeOH) to

give the expected compound CRL 8529 in the form of a yellow solid (6 mg).

- Yield = 11%

- ^1H NMR (CDCl_3): 7.78 (dd, 1H, $J = 8.1$ and 4.8 Hz), 7.97 (ddd, 1H, $J = 8.0$, 7.4 and 1.2 Hz), 8.04 (ddd, 1H, $J = 8.0$, 7.4 and 1.2 Hz), 8.51 (d, 1H, $J = 5.9$ Hz), 8.69 (dd, 2H, $J = 8.0$ and 1.5 Hz), 9.08 (dd, 1H, $J = 4.8$ and 1.9 Hz), 9.13 (d, 1H, $J = 5.9$ Hz), 9.27 (d, 1H, $J = 1.9$ and 8.1 Hz)

- ^{13}C NMR (CDCl_3): 115.15, 121.76, 122.28, 127.13, 127.16, 129.65, 130.82, 132.21, 132.60, 132.99, 136.88, 139.91, 144.85, 148.00, 148.03, 151.75, 151.84, 179.94

- MS (m/z): 283 (54), 255 (100) 228 (10).

15 EXAMPLE 30

5-Bromo-9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one (CRL 8839)

Compound CRL 8839 is prepared according to the procedure described in Example 8, starting with 9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one (CRL 8529) (0.5 g, 1.77 mmol); 20 ml of acetic acid; bromine solution (0.2 ml, 3.88 mmol/5 ml of acetic acid); reflux for 24 hours.

25 EXAMPLE 31

5-Amino-9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one (CRL 8836)

Compound CRL 8836 is prepared according to the procedure described in Example 9, starting with 5-bromo-9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one (CRL 8839) (1.15 g, 18 mmol); 250 ml of DMF; sodium azide (1.2 g, 1.85 mmol); reflux for 4 hours.

EXAMPLE 32

5-(Dimethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-*de*]-[1,7]phenanthrolin-9-one (CRL 8840)

Compound CRL 8840 is prepared according to the procedure described in Example 22, starting with 5-amino-9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one

(CRL 8836) (1.28 g, 4.3 mmol); dimethylformamide diacetal (4 ml, 21.9 mmol); trifluoroacetic acid (12.5 ml, 83 mmol); sodium cyanoborohydride (4.1 g, 65 mmol); 90°C for 8 hours.

5

EXAMPLE 33

5-Bis(chloroethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8841)

Compound CRL 8841 is prepared according to the procedure described in Example 24, starting with 5-amino-9-*H*-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8836) (1 g, 3.95 mmol); chloroacetaldehyde (2.6 ml, 16.8 mmol); acetic acid (30 ml); sodium cyanoborohydride (0.63 g, 10 mmol); 30 minutes at room temperature.

15

EXAMPLE 34

5-(Chloroethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-de]-[1,7]phenanthrolin-9-one (CRL 8842)

Compound CRL 8842 is also obtained during the procedure described in the above example from 5-amino-9-*H*-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8836).

20

EXAMPLE 35

4-Bromo-5-amino-9-*H*-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8843)

Compound CRL 8843 is prepared according to the procedure described in Example 27, starting with 5-amino-9-*H*-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8836) (0.6 g, 2.01 mmol); 24 ml of acetic acid; bromine (35 µl, 0.67 mmol); 50°C for 6 hours.

30

EXAMPLE 36

7-Nitro-9-*H*-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8838)

35

Compound CRL 8838 is prepared according to the procedure described in Example 6, starting with 9-*H*-quino[4,3,2-de][1,7]phenanthrolin-9-one (CRL 8529)

EXAMPLE 37

Compound CRL 8837 is prepared according to the procedure described in Example 7, starting with 7-nitro-9-*H*-quino[4,3,2-*de*][1,7]phenanthrolin-9-one (CRL 8838) (0.2 g, 0.61 mmol); iron (0.19 g, 3.38 mmol), 10 ml of acetic acid/water mixture (50/50).

Compound CRL 8844 is prepared according to the procedure described in Example 29, starting with 3-methoxy-6-methyl-1,11-diazanaphthacene-5,12-dione (Intermediate D₂) (0.76 g, 25 mmol); dimethylformamide diacetal (2 ml, 11.67 mmol); 120°C for 30 minutes; NH₄Cl (4.5 g); 500 ml of ethanol; refluxed for 30 minutes.

30

The evaluation of the maximum tolerated dose was performed on 4- to 6-week-old B6D2F1/Jico mice. The compounds were administered intraperitoneally at increasing doses ranging from 2.5 to 160 mg/kg. The value of the MTD (expressed in mg/kg) is determined from the observation of the survival rate of the

- 47 -

animals over a 14-day period after a single administration of the products under consideration. The change in the weight of the animals is also monitored during this period. When the value of the MTD is greater than 160 mg/kg, the value of the MTD is considered as 160 mg/kg by default.

The results of the estimation of the maximum tolerated dose (MTD) are collated in Table I below:

10

TABLE I

Compounds CRL	MTD (mg/kg)
CRL 8274 (Ascididemin)	20
CRL 8269 (2-bromoleptoclinidone)	40
CRL 8323 (Example 1)	20
CRL 8301 (Example 2)	> 160
CRL 8241 (Example 3)	> 160
CRL 8325 (Example 4)	> 160
CRL 8297 (Example 5)	> 160
CRL 8289 (Example 6)	20
CRL 8344 (Example 7)	> 160
CRL 8248 (Example 8)	> 160
CRL 8347 (Example 9)	> 160
CRL 8292 (Example 13)	> 160
CRL 8290 (Example 12)	80
CRL 8333 (Example 14)	> 160
CRL 8368 (Example 10)	> 160
CRL 8369 (Example 15)	> 160
CRL 8373 (Example 16)	> 160
CRL 8387 (Example 11)	> 160
CRL 8389 (Example 17)	> 160
CRL 8406 (Example 19)	> 160
CRL 8407 (Example 20)	> 160
CRL 8416 (Example 21)	> 160
CRL 8419 (Example 22)	40
CRL 8418 (Example 23)	40
CRL 8422 (Example 24)	> 160
CRL 8423 (Example 25)	> 160

5 The majority of the products described in the family of
ascididemin or of its isomer do not show any direct
toxicity (MTD > 160 mg/kg) and may thus be used *in vivo*
at high tissue concentrations, and thus at high doses.

2 - Cytotoxic activity on tumor cell lines in culture

The influence of the compounds of formulae I and Ia on neoplastic cells was evaluated using the MTT colorimetric test. The principle of the MTT test is based on the mitochondrial reduction by metabolically active live cells of the yellow product MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) into a blue product, formazan. The amount of formazan thus obtained is directly proportional to the amount of live cells present in the culture well(s). This amount of formazan is measured by spectrophotometry.

The cell lines are maintained as a monolayer culture at 37°C in closed culture dishes containing MEM 25 MM HEPES base medium (minimum essential medium). This medium, adapted to the growth of a varied range of mammalian diploid or primary cells, is then supplemented:

- with an amount of 5% FCS (Fetal Calf Serum) decompemented at 56°C for 1 hour,
- with 0.6 mg/ml of L-glutamine,
- with 200 IU/ml of penicillin,
- with 200 mg/ml of streptomycin,
- with 0.1 mg/ml of gentamycin.

The 12 human cancer cell lines used were obtained from the *American Type Culture Collection* (ATCC, Rockville, MD, USA). These 12 cell lines are:

- U-373MG (code ATCC: HTB-17) and U-87MG (code ATCC: HTB-14) which are two glioblastomas,
- SW1088 (code ATCC: HTB-12) which is an astrocytoma,
- A549 (code ATCC: CCL-185) and A-427 (code ATCC: HTB-53) which are two non-small-cell lung cancers,

- 50 -

- HCT-15 (code ATCC: CCL-225) and LoVo (code ATCC: CCL-229) which are two colorectal cancers,
- T-47D (code ATCC: HTB-133) and MCF7 (code ATCC: HTB-22) which are two breast cancers,
- J82 (code ATCC: HTB-1) and T24 (code ATCC: HTB-4) which are two bladder cancers,
- PC-3 (code ATCC: CRL-1435) which is a prostate cancer.

10

Experimentally: 100 µl of a cell suspension containing 20 000 to 50 000 (depending on the cell type used) cells/mL of culture medium are inoculated in flat-bottomed 96-well multi-well plates and are incubated at 37°C under an atmosphere comprising 5% CO₂ and 70% humidity. After incubating for 24 hours, the culture medium is replaced with 100 µl of fresh medium containing either the various test compounds at concentrations ranging from 10⁻⁵ to 10⁻¹⁰ M or the solvent used to dissolve the test products (control condition). After incubating for 72 hours under the above conditions, the culture medium is replaced with 100 µl of a yellowish solution of MTT dissolved at a rate of 1 mg/mL in RPMI 1640. The microplates are reincubated for 3 hours at 37°C and then centrifuged for 10 minutes at 400 g. The yellowish solution of MTT is removed and the blue formazan crystals formed at the cellular level are dissolved in 100 µl of DMSO. The microplates are then agitated for 5 minutes. The intensity of the resulting blue coloration, and thus of the conversion of the yellow MTT product into blue formazan by the cells that are still alive at the end of the experiment is quantified by spectrophotometry using a Dynatech Immunoassay System machine at wavelengths of 570 nm and 630 nm corresponding, respectively, to the maximum absorption wavelengths of formazan and to the background noise. Software built into the spectrophotometer calculates the average

- 51 -

optical density values and also the standard deviation (Std. Dev.) and standard error of mean (SEM) values.

The inhibitory activity on the cell growth of the compounds of formulae I and Ia on the different tumor cell lines was compared with that of the natural product ascididemin (CRL 8274). All of the compounds show significant inhibitory activity on the cell proliferation of the 12 human tumor lines: U-87MG, U-373MG, SW 1088, T24, J82, HCT-15, LoVo, MCF7, T-47D, A549, A-427 and PC-3 with a 50% inhibitory concentration (IC_{50}) which is between $10^{-6}M$ and $10^{-10}M$, depending on the compounds and the tumor lines tested. By way of example, the values of the concentrations flanking the IC_{50} values which are obtained on the various cell lines are given in Table II:

TABLE II

COMPOUNDS	CELL LINES												
	CRL	U-87MG	U-373MG	SW1088	T24	J82	HCT-15	LoVo	MCF7	T-47D	A549	A-427	PC-3
CRL8274		$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-8}, 10^{-9}]$
CRL8289		$[10^{-8}, 10^{-9}]$	$[10^{-8}, 10^{-9}]$	$[10^{-8}, 10^{-9}]$	$[10^{-8}, 10^{-9}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-8}, 10^{-9}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-8}, 10^{-9}]$	$[10^{-6}, 10^{-7}]$
CRL8248		$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$
CRL8241		$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$
CRL8297		$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$
CRL8301		$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$
CRL8323		$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$
CRL8325		$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-8}, 10^{-9}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-8}, 10^{-9}]$	$[10^{-7}, 10^{-8}]$
CRL8344		$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-5}, 10^{-6}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$
CRL8347		$[10^{-7}, 10^{-8}]$	$[10^{-8}, 10^{-9}]$	$[10^{-7}, 10^{-8}]$	$[10^{-8}, 10^{-9}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-5}, 10^{-6}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-8}, 10^{-9}]$	$[10^{-8}, 10^{-9}]$	$[10^{-6}, 10^{-7}]$
CRL8368		$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-8}, 10^{-9}]$	$[10^{-5}, 10^{-6}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$
CRL8369		$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-6}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-5}, 10^{-6}]$	$[10^{-6}, 10^{-7}]$	$[10^{-5}, 10^{-6}]$
CRL8373		$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-5}, 10^{-6}]$	$[10^{-6}, 10^{-7}]$	$[10^{-5}, 10^{-6}]$
CRL8387		$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-6}, 10^{-7}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-6}, 10^{-7}]$	$[10^{-5}, 10^{-6}]$
CRL8389		$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-5}, 10^{-6}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$
CRL8268*		$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$>10^{-5}$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$
CRL8322*		$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$>10^{-5}$	$>10^{-5}$	$>10^{-5}$	$[10^{-5}, 10^{-6}]$	$>10^{-5}$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$>10^{-5}$
CRL8324**		$[10^{-5}, 10^{-6}]$	$>10^{-5}$	$>10^{-5}$	$>10^{-5}$	$>10^{-5}$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$	$[10^{-5}, 10^{-6}]$
CRL8422		$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-5}, 10^{-6}]$	$[10^{-6}, 10^{-7}]$	$[10^{-6}, 10^{-7}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-6}, 10^{-7}]$
CRL8423		$[10^{-8}, 10^{-9}]$	$[10^{-8}, 10^{-9}]$	$[10^{-9}, 10^{-10}]$	$[10^{-9}, 10^{-10}]$	$[10^{-8}, 10^{-9}]$	$[10^{-8}, 10^{-9}]$	$[10^{-7}, 10^{-8}]$	$[10^{-7}, 10^{-8}]$	$[10^{-5}, 10^{-6}]$	$[10^{-7}, 10^{-8}]$	$[10^{-9}, 10^{-10}]$	$[10^{-7}, 10^{-8}]$

Inhibitory concentrations (M) flanking the value of the 50% inhibitory concentration of the compounds of formula I, II(*) or III(**) on the cell lines

Table III gives the results of the average IC_{50} values (in nM) (calculated from the cytotoxic activity on the 12 tumor lines studied) and the MTD/ IC_{50} ratios (these ratios are calculated by forming the ratio of the MTD values and the IC_{50} values expressed as numbers without units).

TABLE III

Compounds CRL	IC_{50} (nM)	MTD/ IC_{50}	MTD/ IC_{50} *
CRL 8274 (Ascididemin)	100	0.20	1
CRL 8269 (2-bromoleptoclinidone)	120	0.33	2
CRL 8289 (Example 6)	10	2.00	10
CRL 8248 (Example 8)	80	2.00	10
CRL 8241 (Example 3)	140	1.14	6
CRL 8297 (Example 5)	90	1.78	9
CRL 8325 (Example 4)	37	4.32	22
CRL 8344 (Example 7)	53	3.02	15
CRL 8347 (Example 9)	21	7.62	38
CRL 8323 (Example 1)	60	0.33	2
CRL 8301 (Example 2)	270	0.59	3
CRL 8389 (Example 17)	420	0.38	2
CRL 8368 (Example 10)	480	0.33	2
CRL 8406 (Example 19)	60	2.67	13
CRL 8407 (Example 20)	22	7.27	36
CRL 8416 (Example 21)	80	2.00	10
CRL 8418 (Example 23)	110	0.37	2
CRL 8419 (Example 22)	60	0.67	3.3
CRL 8422 (Example 24)	100	1.60	8.3
CRL 8423 (Example 25)	7	22.86	114

10 *: the ratio MTD/ IC_{50} for the various compounds was estimated by taking as reference a ratio equal to 1 for ascididemin.

15 The compounds described show, on the tumor cell line models, IC_{50} values (nM) which are greater than or equivalent to that of ascididemin. With the exception

of CRL 8289 (whose maximum tolerated dose is equivalent to that of ascididemin, but whose IC_{50} value is ten times lower than that of ascididemin), the maximum tolerated doses of the compounds described, considered
5 by default as equivalent to 160 mg/kg, are markedly higher than those of ascididemin (20 mg/kg). These results suggest that this novel family of compounds have no direct toxicity. Consequently, the tolerance/cytotoxic activity ratios of the compounds
10 illustrated in the present invention are markedly higher than that of the natural ascididemin. These compounds may thus be used as antitumor drugs, for their cytotoxic properties, at tissue concentrations that are higher than those induced with the natural
15 ascididemin. They are thus characterized by better therapeutic manageability. CRL 8289, whose IC_{50} value is 10 nM, also shows better therapeutic manageability than ascididemin.

20 By virtue of their cytotoxic properties, the compounds of formulae I and Ia as described, or in the form of acceptable pharmaceutical salts or solvates, may be used as active principles of drugs.

25 The compounds of formulae I and Ia are generally administered in dosage units established either per m^2 of body surface or per kg of weight. Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed
30 with one (or more) pharmaceutical excipient(s).

The compounds of formulae I and Ia may be used, according to the cancer pathology of the individual to be treated, at doses of between 0.05 and 350 mg/m^2 of
35 body surface, preferably at doses from 0.5 to 50 $mg/m^2/day$ for a curative treatment in the acute phase as a function of the number of treatment cycles of each cure. For maintenance treatment, the compounds of formulae I and Ia will advantageously be used at

5

10

15


20

25


testicular tumors.

CLAIMS

1. A pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of general formulae I and Ia below for treating, by virtue of their cytotoxic properties, cancerous tumors and their metastases:



Formula I



Formula Ia

in which:

- X is chosen from oxygen, an =NH group and an =N-OH group,

- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,


- R₂ is chosen from hydrogen and halogens,

- R₃ is chosen from hydrogen, halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl groups and groups -(CH₂)_n-Y with Y being chosen from halogens and CN, -CH(O-Et)₂, (C₁-C₆) alkoxy, -O-(CH₂)₂-N(CH₃)₂ and -N(CH₃)₂ groups and n = 1 to 3,

- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₅, R₆ and R₇ are chosen from:
hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy,
 (C_1-C_6) alkoxy (C_1-C_6) alkyl, (C_1-C_4) alkylcarbonyloxy-
 (C_1-C_4) alkyl, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄
 and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which
 R₁₄ and R₁₅ are chosen, independently of each
 other, from hydrogen and (C_1-C_6) alkyl, -phenyl-CO-
 CH₃ and -CH₂-CH₂-N(CH₃)₂ groups,
 -phenyl-CO-CH₃ or -phenyl-CO-CH=CH-
 N(CH₃)₂, morpholino, nitro or SO₃H groups,
 groups:



R₁₆ and R₁₇ being chosen from C_1-C_6 alkyl groups and
 Ar being a C_6-C_{14} aryl group,
 with the exclusion of the compounds of formula I
 containing the combination:

X = O,

and, either : R₁, R₂, R₃, R₄, R₅, R₆,
 R₇ = H,

or : R₁, R₃, R₄, R₅, R₆, R₇ = H and

R₂ = Br,

or R₁, R₂, R₃, R₄, R₆, R₇ = H and R₅ = OH

and with the exclusion of the compound formula Ia
 containing the combination X = O and R₁, R₂, R₃,
 R₄, R₅, R₆, R₇ = H,

and the addition salts of these compounds
 with pharmaceutically acceptable acids.

2. A pharmaceutical composition comprising an
 effective amount of a compound chosen from the
 compounds of formula I in which:

- X is chosen from oxygen, an =NH group
 and an =N-OH group,

- R₁ is chosen from hydrogen, halogens, a
 nitro group and groups -NR₈R₉ in which R₈ and R₉

- 59 -

are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₂ is chosen from hydrogen and halogens,

- R₃ is chosen from hydrogen, halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenyl-alkyl, -(CH₂)₂-N(CH₃)₂, and -(CH₂)₂-O-(CH₂)₂-N(CH₃)₂ groups,


- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₅, R₆ and R₇ are chosen from:

hydrogen or a halogen atom,

C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ groups in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl and -CH₂-CH₂-N(CH₃)₂ groups,

-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂, morpholino, nitro or SO₃H groups, groups:



R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,

with the exclusion of the compounds in which X = O, and, either : R₁, R₂, R₃, R₄, R₅, R₆, R₇ = H, or : R₁, R₃, R₄, R₅, R₆, R₇ = H and R₂ = Br, or R₁, R₂, R₃, R₄, R₆, R₇ = H and R₅ = OH,

and the addition salts of these compounds with pharmaceutically acceptable acids.

AMENDED SHEET

3. The pharmaceutical composition as claimed in claim 2, comprising an effective amount of a compound chosen from the compounds of formula I in which:

- X represents oxygen,
- 5 - R₁ is chosen from hydrogen and an amino group,
- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from hydrogen, halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a
- 10 guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, methyl groups, (C₁-C₄) phenylalkyl, - (CH₂)₂-N(CH₃)₂, - (CH₂)₂-O- (CH₂)₂-N(CH₃)₂ groups,
- R₄ is chosen from hydrogen, halogens and
- 15 nitro and amino groups,
- R₅, R₆ and R₇ represent a hydrogen, with the exclusion of the compounds in which R₁, R₂, R₃, R₄, R₅, R₆, R₇ = H, or R₁, R₃, R₄, R₅, R₆, R₇ = H and R₂ = Br,
- 20 and the addition salts of these compounds with pharmaceutically acceptable acids.

4. The pharmaceutical composition as claimed in claim 1, comprising an effective amount of a compound chosen from the compounds of formulae I and Ia in which:

- X represents oxygen,
- R₁ is chosen from hydrogen and an amino group,
- 30 - R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from hydrogen, halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a
- 35 guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, methyl groups, (C₁-C₄) phenylalkyl groups and groups - (CH₂)_n-Y with Y being chosen from halogens and groups CN, -CH(O-Et)₂, (C₁-C₆) alkoxy, -O- (CH₂)₂-N(CH₃)₂ and -N(CH₃)₂ and n = 1 to 3,

... R₄ is chosen from hydrogen, halogens, and nitro and amino groups,

- R₅ is chosen from a hydrogen, a halogen and a methoxy group,

5 - R_6 and R_7 are chosen from hydrogen and
 C_1-C_6 alkoxy, (C_1-C_6) alkoxy (C_1-C_6) alkyl and
 $-CH_2OCOCH_3$ groups,

10 with the exclusion of the compounds of formula I in which $R_1, R_2, R_3, R_4, R_5, R_6, R_7 = H$ or $R_1, R_3, R_4, R_5, R_6, R_7 = H$ and $R_2 = Br$, and of the compound of formula Ia in which $R_1, R_2, R_3, R_4, R_5, R_6, R_7 = H$,

and the addition salts of these compounds with pharmaceutically acceptable acids.

15

5. The composition as claimed in claim 4, in which the compounds are chosen from:

5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthroline-9-one,

20 5-(benzylamino)-9H-quin[4,3,2-de][1,10]phenan-
throlin-9-one,

5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

25 7-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

30 10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-
9-one,

5-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

35 7-nitro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

- 62 -

5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
 5- (dimethylamino-2-ethyl) amino-9H-quino[4,3,2-de]-
 [1,10]phenanthrolin-9-one,
 5 5-bis (2-chloroethyl) amino-9H-quino[4,3,2-de]-
 [1,10]phenanthrolin-9-one,
 5- (2-chloroethyl) amino-9H-quino[4,3,2-de][1,10]-
 phenanthrolin-9-one,
 12-methoxy-9-H-quino[4,3,2-de][1,10]phenanthrolin-
 10 9-one,
 4-bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenan-
 throlin-9-one,
 11-acetoxymethyl-9-H-quino[4,3,2-de][1,10]phenan-
 throlin-9-one,
 15 5-bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-
 one,
 5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-
 one,
 5- (dimethylamino-2-ethyl) amino-9-H-quino[4,3,2-
 20 de][1,7]phenanthrolin-9-one,
 5-bis (chloroethylamino-2-ethyl) amino-9-H-quino-
 [4,3,2-de][1,7]phenanthrolin-9-one,
 5- (chloroethylamino-2-ethyl) amino-9-H-quino[4,3,2-
 de][1,7]phenanthrolin-9-one,
 25 4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenan-
 throlin-9-one,
 7-nitro-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-
 one,
 7-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-
 30 one,
 12-methoxy-9-H-quino[4,3,2-de][1,7]phenanthrolin-
 9-one,
 and the addition salts thereof with
 pharmaceutically acceptable acids.

35

6. The use of a compound as defined in one of claims 1 to 5, for the manufacture of an anticancer drug.

- 63 -

7. The use as claimed in claim 6, in which the compounds are chosen from:

5- (dimethylamino) -9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5 5- (benzylamino) -9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

10 7-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

15 10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

7-nitro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

20 5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

25 5- (dimethylamino-2-ethyl) amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bis (2-chloroethyl) amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

30 5- (2-chloroethyl) amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

12-methoxy-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

35 11-acetoxymethyl-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

AMENDED SHEET

- 64 -

5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-bis(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,


7-nitro-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

7-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,


12-methoxy-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

and the addition salts thereof with pharmaceutically acceptable acids.

8. Compounds of general formulae I and Ia



Formula I



Formula Ia

in which:

- X is chosen from oxygen, an =NH group and an =N-OH group,

- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,


- R₂ is chosen from hydrogen and halogens,

- R₃ is chosen from hydrogen, halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a

guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl groups and groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN , $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ and $=N(CH_3)_2$ groups and $n = 1$ to 3 ,

$- R_4$ is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

$- R_5, R_6$ and R_7 are chosen from:
hydrogen or a halogen atom,
 C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, (C_1-C_6) alkoxy (C_1-C_6) alkyl, (C_1-C_4) alkylcarbonyloxy-
 (C_1-C_4) alkyl, $-CHO$, $-COOH$, $-CN$, $-CO_2R_{14}$, $-CONHR_{14}$
and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl, $-phenyl-CO-CH_3$ and $-CH_2-CH_2-N(CH_3)_2$ groups,
 $-phenyl-CO-CH_3$ or $-phenyl-CO-CH=CH-N(CH_3)_2$, morpholino, nitro or SO_3H groups,
groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,

with the exclusion of the compounds of formula I in which $X = O$, and, either $R_1, R_2, R_3, R_4, R_5, R_6, R_7 = H$, or $R_1, R_3, R_4, R_5, R_6, R_7 = H$ and $R_2 = Br$, or $R_1, R_2, R_4, R_5, R_6, R_7 = H$ and $R_3 = OCH_3$, or $R_1, R_2, R_3, R_4, R_6, R_7 = H$ and $R_5 = OH$ or OCH_3 , or $R_1 = NO_2$ and $R_2, R_3, R_4, R_5, R_6, R_7 = H$,

and with the exclusion of the compound formula Ia in which $X = O$ and $R_1, R_2, R_3, R_4, R_5, R_6, R_7 = H$,

and the addition salts of these compounds with pharmaceutically acceptable acids.

9. Compounds as claimed in claim 8, of formula I in which:

- X is chosen from oxygen, an =NH group and an =N-OH group,

- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₂ is chosen from hydrogen and halogens,

- R₃ is chosen from hydrogen, halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl, -(CH₂)₂-N(CH₃)₂, and -(CH₂)₂-O-(CH₂)₂-N(CH₃)₂ groups,


- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₅, R₆ and R₇ are chosen from:

hydrogen or a halogen atom,

C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl and -CH₂-CH₂-N(CH₃)₂ groups,

-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂, morpholino, nitro or SO₃H groups, groups:



R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,

5 with the exclusion of the compounds in which
X = O, and, either R₁, R₂, R₃, R₄, R₅, R₆, R₇ = H,
or R₁, R₃, R₄, R₅, R₆, R₇ = H and R₂ = Br, or R₁, R₂,
R₄, R₅, R₆, R₇ = H and R₃ = OCH₃, or R₁, R₂, R₃, R₄,
R₆, R₇ = H and R₅ = OH or OCH₃, or R₁ = NO₂ and R₂,
10 R₃, R₄, R₅, R₆, R₇ = H,
and the addition salts thereof with
pharmaceutically acceptable acids.

10. Compounds as claimed in claim 8, which are:
- 15 5-(dimethylamino)-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
5-(benzylamino)-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
5-bromo-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
20 7-amino-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
5-amino-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
5-methyl-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
5-chloro-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
5-bromo-10-methoxy-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-
25 9-one,
5-(dimethylamino-2-ethyl) amino-9*H*-quino[4,3,2-*de*][1,10]-phenanthrolin-9-one,
5-bis(2-chloroethyl) amino-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
30 5-(2-chloroethyl) amino-9*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
12-methoxy-9-*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,
4-bromo-5-amino-9-*H*-quino[4,3,2-*de*][1,10]phenanthrolin-9-one,

11-acetoxymethyl-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
5-(dimethylamino-2-ethyl)amino-9-H-quino[4,3,2-de]-
[1,7]phenanthrolin-9-one,
5-bis(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de]-
[1,7]phenanthrolin-9-one,
5-(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de]-
[1,7]phenanthrolin-9-one,
4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
7-nitro-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
7-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
12-methoxy-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
and the addition salts thereof with pharmaceutically acceptable acids.

11. A process for preparing a compound of formula Ia, in which:

- X is chosen from oxygen, an =NH group and an =N-OH group,

- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₂ is chosen from hydrogen and halogens,

- R₃ is chosen from hydrogen, halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl groups and groups -(CH₂)_n-Y with Y being chosen from halogens and CN, -CH(O-Et)₂, (C₁-C₆) alkoxy, -O-(CH₂)₂-N(CH₃)₂ and -N(CH₃)₂ groups and n = 1 to 3,

- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃

- 69 -


are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₅, R₆ and R₇ are chosen from:

hydrogen or a halogen atom,


C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, (C₁-C₆) alkoxy (C₁-C₆) alkyl, (C₁-C₄) alkyl carbonyloxy- (C₁-C₄) alkyl, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl, -phenyl-CO-CH₃ and -CH₂-CH₂-N(CH₃)₂ groups,

-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂, morpholino, nitro or SO₃H groups, groups:




R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group, which consists in:

a - condensing a chlorobenzoic acid of formula:




with a dimethoxyaniline of formula:

- 70 -




to give a compound of formula IIa:



5


b - cyclizing the compound of formula IIa to give a compound of formula:



10


c - converting the compound into a quinone of formula IIIa:

- 71 -




d - reacting the quinone of formula IIIa with an azadiene of formula:

5



to give a compound of formula IVa:



10


e - reacting the compound of the formula IVa with dimethylformamide diethyl acetal to give the compound of formula Ia,

15

f - and, optionally, converting the compound thus obtained into another compound of formula Ia.

12. A process for treating patients having a cancer tumor, which consists in administering an effective amount of a compound as defined in claim 1.

13. A process for preparing compounds of general formula I, of formula:



in which:

- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-NR_8R_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_2 is chosen from hydrogen and halogens,

- R_3 is chosen from hydrogen, halogens, (C_1-C_4) alkyl groups, (C_1-C_6) alkoxy groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl groups and groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN , $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ groups and $-N(CH_3)_2$ and $n = 1$ to 3,


- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_5 , R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, (C₁-C₄)alkylcarbonyloxy-(C₁-C₄)alkyl, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl, -phenyl-CO-CH₃ and -CH₂-CH₂-N(CH₃)₂ groups,

-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂, morpholino, nitro or SO₃H groups, groups:




R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,

with the exclusion of the compounds of formula I in which either R₁, R₂, R₃, R₄, R₅, R₆, R₇ = H, or R₁, R₃, R₄, R₅, R₆, R₇ = H and R₂ = Br, or R₁, R₂, R₄, R₅, R₆, R₇ = H and R₃ = OCH₃, or R₁, R₂, R₃, R₄, R₆, R₇ = H and R₅ = OH or OCH₃ or R₁ = NO₂ and R₂, R₃, R₄, R₅, R₆, R₇ = H,


which consists

a) in reacting a hydroquinone of formula




with a compound of formula

- 74 -




in the presence of CeCl_3 , $7\text{H}_2\text{O}$ and ethanol to give a compound of formula II

5




b) in converting the compound of formula II into a compound of formula III

10



c) in reacting the compound of the formula III with $\text{HC}(\text{OC}_2\text{H}_5)_2\text{N}(\text{CH}_3)_2$ in DMF at 120°C to form a compound of formula IV

15




- 75 -

d) in cyclizing the compound of formula IV to a compound of formula I in the presence of NH_4Cl and AcOH ,

5

e) optionally converting the compound of formula I thus obtained into another compound of formula II.

10 14. A compound of formula



in which:

15

- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-\text{NR}_8\text{R}_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and $(\text{C}_1\text{-C}_4)$ alkyl groups,

20

- R_2 is chosen from hydrogen and halogens,

- R_3 is chosen from hydrogen, halogens, $(\text{C}_1\text{-C}_4)$ alkyl groups, $(\text{C}_1\text{-C}_6)$ alkoxy groups, a guanidino group, groups $-\text{NR}_{10}\text{R}_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, $(\text{C}_1\text{-C}_4)$ alkyl groups, $(\text{C}_1\text{-C}_4)$ phenylalkyl groups and groups $-(\text{CH}_2)_n\text{-Y}$ with Y being chosen from halogens and CN , $-\text{CH}(\text{O-Et})_2$, $(\text{C}_1\text{-C}_6)$ alkoxy, $-\text{O}-(\text{CH}_2)_2\text{-N}(\text{CH}_3)_2$ and $-\text{N}(\text{CH}_3)_2$ groups and $n = 1$ to 3 ,

25

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-\text{NR}_{12}\text{R}_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and $(\text{C}_1\text{-C}_4)$ alkyl groups,

30

- R_5 , R_6 and R_7 are chosen from:


AMENDED SHEET

- 76 -

hydrogen or a halogen atom, ...

C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, (C₁-C₄)alkylcarbonyloxy-(C₁-C₄)alkyl, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl, -phenyl-CO-CH₃ and -CH₂-CH₂-N(CH₃)₂ groups,

-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂, morpholino, nitro or SO₃H groups, groups:



R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group, with the exclusion of compounds in which either R₁, R₂, R₃, R₄, R₅, R₆, R₇ = H, or R₁, R₃, R₄, R₅, R₆, R₇ = H and R₂ = Br, or R₁, R₂, R₄, R₅, R₆, R₇ = H and R₃ = OCH₃, or R₁, R₂, R₃, R₄, R₆, R₇ = H and R₅ = OH or OCH₃ or R₁ = NO₂ and R₂, R₃, R₄, R₅, R₆, R₇ = H, and the addition salts of these compounds with pharmaceutically acceptable acids.

Ref. _____

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Phenanthroline-7-one derivatives and their therapeutic applications

the specification of which: *(check one)*

REGULAR OR DESIGN APPLICATION

- ☒ is attached hereto.
- ☐ was filed on _____ as application Serial No. _____ and was amended on _____ (if applicable).

PCT FILED APPLICATION ENTERING NATIONAL STAGE

- ☐ was described and claimed in International application No. PCTFR00/02312 filed on 11/08/2000 and as amended on _____ (if any).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under 35 USC 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATION(S)

Country	Application Number	Date of Filing (day, month, year)	Priority Claimed
FRANCE	9910490	13/08/99	YES
FRANCE	0006652	24/05/00	YES

(Complete this part only if this is a continuing application.)

I hereby claim the benefit under 35 USC 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 USC 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status--patented, pending, abandoned)

[illegible]

As a named inventor, I hereby appoint the registered patent attorneys represented by Customer No. **000466** to prosecute this application and transact all business in the Patent and Trademark Office connected therewith, including: **Robert J. PATCH, Reg. No. 17,355, Andrew J. PATCH, Reg. No. 32,925, Robert F. HARGEST, Reg. No. 25,590, Benoît CASTEL, Reg. No. 35,041, Eric JENSEN, Reg. No. 37,855, Thomas W. PERKINS, Reg. No. 33,027, and Roland E. LONG, Jr., Reg. No. 41,949.**

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

2. Once the problem is identified, the next step is to define the objectives of the project. These objectives should be clear, measurable, and achievable.

3. The third step is to develop a plan of action. This involves identifying the resources needed, the tasks to be completed, and the timeline for the project.

4. The fourth step is to implement the plan. This involves assigning responsibilities, monitoring progress, and making adjustments as needed.

5. The final step is to evaluate the results of the project. This involves comparing the actual outcomes to the objectives and identifying areas for improvement.

00466

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventor's signature _____

Date 30/11/01

Residence: 4, Impasse du Liège 66450 POLLESTRES - FRANCE Citizenship: FRENCH

Post Office Address: The same as above

Inventor's signature

Date 05/12/01

Residence: Avenue V. Olivier - Bâtiment 8A, Boîte 60

Citizenship: FRENCH

1070 BRUXELLES - BELGIQUE

Post Office Address: The same as above

Inventor's signature

Date 30/11/2001

Residence: 20 Rue Antoine Carbo - 66000 PERPIGNAN - FRANCE Citizenship: FRENCH

Post Office Address: The same as above

Inventor's signature

Date 5/12/01

Residence: 4 Cours au bois -1440 WAUTHIER-BRAINE -
Belgique

Citizenship: Belgian

Post Office Address: The same as above

Full name of fifth joint inventor, if any: Armand FRYDMAN
(given name, family name)

Inventor's signature

Date _____

Residence: 10 allée des Fusains - 91370 VERRIERES LE BUISSON FRANCE Citizenship: FRENCH

Post Office Address: The same as above

Full name of sixth joint inventor, if any:
(given name, family name)

Inventor's signature

Date

Residence:

Citizenship:

Post Office Address: